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1
Venous thrombosis
Clot formation is a natural and vital mechanism in quickly sealing disruption of vessel 
walls, thereby preventing excessive bleeding. Vessel wall disruption leads to tissue factor 
exposure to the blood which induces factor X conversion into factor Xa, subsequent ac-
tivation of prothrombin into thrombin, and finally activation of fibrinogen into insoluble 
fibrin. Platelets aggregate at the site of the injury and together with fibrin a blood clot 
is formed. Once in place, a clot is not a passive entity but the result of a delicate balance 
between pro- and anticoagulant activity. When the vessel wall is sufficiently repaired, 
procoagulant activity is reduced again by plasmin, which degrades fibrin clots. This will 
reduce and eventually eliminate the clot. However, if coagulation is overactivated or if 
inhibition is incomplete or fails, excessive clot formation occurs. [1] Situations in which 
this excessive thrombus formation blocks the vein and hinders blood flow, are called 
venous thrombosis. The two main clinical manifestations of venous thrombosis are deep 
vein thrombosis of the lower extremities (deep venous thrombosis of the leg, DVT) and 
embolisation of a dislodged clot to the pulmonary arteries (pulmonary embolism, PE).
Venous thrombosis is a common disease of which the annual incidence is approxi-
mately 1 per 1000 persons. [2] In young and middle-aged individuals many risk factors 
have been established such as immobilisation, oral contraceptives, surgery, fractures, 
and the use of plaster casts. Furthermore, genetic risk factors such as the factor V Leiden 
mutation are known to increase the risk of venous thrombosis. [3] With age, the incidence 
of venous thrombosis increases sharply. [4] E.g., the incidence of venous thrombosis 
is more than 10-fold higher in octogenarians than in middle-aged individuals (40-50 
years). Venous thrombosis will pose an increasing medical and economic burden in the 
future, given the worldwide growth of the older population. In developed countries, in 
the upcoming five decades the number of people of 70 years and older will quadruple. 
[5] In the Netherlands, 15% of the population is 65 years and older, which will increase to 
25% in de next 30 years. [6] This shift in the age distribution in the population will lead 
to an increase in the prevalence and incidence of diseases such as venous thrombosis, 
which will be challenging for policy makers and healthcare professionals. Due to the 
increased incidence of venous thrombosis in older age, an improved understanding of 
the etiology of this disease is specifically needed in the older population in order to 
target adequate preventive measures.
Virchow has described three mechanisms that contribute to thrombus formation. Stasis 
of blood flow, damage to the vessel wall (e.g., by hypoxia) and changes in blood compo-
sition. [7] It is unknown what causes the increase of the incidence of venous thrombosis 
in the older people, i.e., what is the role in older individuals of the well-known ‘’conven-
tional’ risk factors of thrombosis, such as immobilisation due to hospital admission and 
surgery, and whether we can distinguish age-specific risk factors for thrombosis.
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In general, there is a lack of studies involving older people. This phenomenon, referred 
to as “ageism”, has occurred in several fields of medical research. This may have practical 
reasons, e.g., when researchers anticipate mobility problems for older people to reach 
the study centre, or when excluding older people is inherent to the study question, 
e.g., researchers expect genetic risk factors to stand out most in young individuals. 
The difficulties of recruiting older people for research are illustrated by the ‘Multiple 
Environmental and Genetic Assessment of risk factors for venous thrombosis’ (MEGA) 
study [8], a large case-control study on risk factors of venous thrombosis in 18-80 years 
old individuals performed in the Netherlands (1999-2004). This study discontinued the 
recruitment of individuals aged 70 to 80 after one year due to a low participation rate 
(MEGA-study, data not published). In 2007, our study group reported that few risk factors 
have been studied in older people. [9] Knowledge about conventional and age-specific 
risk factors for venous thrombosis in the older population is insufficient. This was the 
rationale behind the “Age and Thrombosis, Acquired and Genetic risk factors in the 
Elderly”, or AT-AGE study, a case-control study among older individuals.
the At-AGe study
The AT-AGE study is a two-centre, population based case-control study in Leiden, the 
Netherlands and Burlington, Vermont, US. From June 2008 to August 2011 in Leiden 
and December 2008 to July 2011 in Vermont, all consecutive patients aged 70 years and 
older with deep venous thrombosis (DVT) in the leg or a pulmonary embolism (PE), were 
identified. In Leiden, cases were identified from two anticoagulation clinics in a defined 
geographical area in the western part of the Netherlands. In Vermont, cases were identi-
fied in the Vascular Laboratory and the Radiology department of University of Vermont 
Health Centre, Burlington. Control subjects were randomly selected from primary care 
practices in Leiden and Vermont. The AT-AGE study was specifically designed to optimise 
the participation-rate in the older population. Therefore, we performed home visits to 
all participants. A home visit enabled us to perform an interview, rather than sending a 
questionnaire, since the latter is often difficult for older individuals leading to a decrease 
in the participation rate. The interview assessed conventional thrombosis risk factors 
that have been established in young and middle-aged people and putative age-specific 
risk factors, e.g., the presence of varicose veins and functional status. The interview was 
conducted by trained research assistants, in order to minimise missing data and poten-
tial misinterpretation of questions by the participant. In addition, during the home visits 
a blood sample was drawn and we performed multiple anthropometric measurements 
and physical tests relevant in the older population, e.g., hand grip strength and gait 
speed.
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outline of this thesis
The main objective of this thesis is to determine the risk of venous thrombosis associ-
ated with conventional and age-specific risk factors in older people. Moreover, the 
contribution of these risk factors to the increased incidence of venous thrombosis in 
older people is assessed. To this aim, we review, in chapter 2, the current literature (until 
2010) on the effects of conventional risk factors as well as age-specific risk factors for 
venous thrombosis in older people. In chapter 3 we elucidate to what extent immobility 
is a risk factor for thrombosis in older people. We assess the risk of venous thrombosis as-
sociated with hospitalisation, surgery, fracture, plaster cast (or splint) use, minor injuries, 
and transient immobility at home. In chapter 4 we assess whether the two common 
genetic risk factors in younger people, i.e. factor V Leiden (FVL, rs6025) and prothrombin 
20210A mutation (PT20210, rs1799963) are risk factors for a first venous thrombosis at 
older age. Moreover, the association of non-O blood type, and a positive family history of 
thrombosis and thrombosis is determined. In chapter 5 and 6 we focus on “age-specific” 
risk factors. In chapter 5 we determine the risk of venous thrombosis associated with 
clinical features of venous insufficiency, specifically a history of varicose veins, leg ulcer, 
and the presence of leg oedema. In chapter 6 we focus on the presence of functional 
impairment in older individuals and the risk of venous thrombosis. In chapter 7 we 
study the participation rate of older patients in research studies with a focus on practical 
aspects of the study design (i.e., home visits instead of inviting participants to a study 
centre). Because in the AT-AGE study blood samples are obtained at home, these could 
not be processed directly. In chapter 8, we study whether the time between venipunc-
ture and blood processing and difference in storage temperature affected the levels 
fibrinogen, prothrombin, factors VIII, IX, XI and anti-thrombin. Finally, in chapter 9, we 
summarise the main results of this thesis and reflect on the strength and limitations of 
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AbstrACt
Ageing is the strongest risk factor for venous thrombosis. The cause of this steep age-
gradient is as yet, unexplained. The aim of this review was to provide an overview of 
studies on the effect of conventional risk factors as well as age-specific risk factors for 
venous thrombosis in the elderly.
Limited data are available on risk factors for venous thrombosis in the elderly, i.e., all 
results are based on small study groups. Results indicate that, of the conventional risk 
factors, malignant disease, the presence of co-morbidities and the genetic risk factors 
factor V Leiden and the prothrombin mutation seem to be associated with an increased 
risk of venous thrombosis in the elderly. Age-specific risk factors of thrombosis, i.e., 
endothelial dysfunction, diminished muscle strength, and frailty may be important in 
the explanation of the increased incidence of venous thrombosis in the elderly.
In conclusion, since ageing is the strongest risk factor for venous thrombosis, further 
identification of the risk factors for thrombosis in the elderly is needed to elucidate the 
age-gradient of the incidence of venous thrombosis and to target preventive measures.
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introduCtion
Thrombosis in the venous system, i.e., deep venous thrombosis or pulmonary embolism is 
a multicausal disease. The well-established or “conventional” risk factors are mostly identi-
fied in young and middle-aged populations. Conventional risk factors can be acquired, 
e.g., immobility, surgery, malignant disease, and hormone use, whereas the most well-
known genetic risk factors are deficiencies of natural anticoagulants protein C, protein 
S, and antithrombin and the Factor V Leiden and prothrombin 20210A mutations [1-3].
The overall incidence of a first symptomatic venous thrombosis in the general 
population is 1-2 per 1000 person-years (py). In the age-group 25 to 30 years old, venous 
thrombosis occurs in ~1 per 10,000 py as compared to nearly 8 per 1000 py in the 85 
years and older population [4]. The risk of developing venous thrombosis is therefore 
80-fold increased in the older population, leading to a high attributable risk. The popula-
tion attributable risk is more than 90%, indicating that 90% of the total incidence of 
thrombosis in the population can be ascribed to ageing. The life-time risk (cumulative 
incidence) of venous thrombosis is up to 15% in those aged 90, and ~60% of all venous 
thrombosis events occur in those aged 70 years and older [4].
It is therefore clear that ageing is by far the strongest risk factor for venous throm-
botic disease, resulting in a high incidence of venous thrombosis in the elderly 

























figure 1. Incidence of first venous thrombosis (VT) [deep vein thrombosis (DVT) and pulmonary embo-
lism (PE)] stratified by age group and gender. Rates are shown by 1000 per year, for man in open bars , for 
women in closed bars. *Adapted from Naess et al. (2007).
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by an increased prevalence of conventional risk factors and the presence of other, age-
specific, risk factors. The incidence of venous thrombosis is similar for men and women 
indicating that, given the excess of women in the old age groups, most elderly patients 
with venous thrombosis are women [5]. Furthermore, a difference in the distribution of 
deep venous thrombosis and pulmonary embolism between young and old people has 
been described. In one study in middle-aged individuals (40 to 44 years old) deep vein 
thrombosis (incidence of 0.3/1000 py) was three times more frequent than pulmonary 
embolism (incidence of 0.1/1000 py) [6]. In patients of 80 to 84 years old, pulmonary 
embolism (incidence of 5.5/1000 py) was more frequently diagnosed than deep vein 
thrombosis (incidence of 3.0/1000 py) [6]. These findings suggest that also an increase 
in the embolisation of clots may contribute to the age-gradient. However, in contrast, 
a large European registry found that deep vein thrombosis was more often diagnosed 
than pulmonary embolism in the 80 to 84 year old individuals (incidences of 3.8/1000 py 
for deep vein thrombosis compared to 2.2/1000 py for pulmonary emboli) [4].
In general, people over 60 years are considered to be ‘the elderly’ [5]. Why does throm-
bosis incidence increase with age? Several explanations can be postulated. Ageing may 
be associated with an increased prevalence of conventional risk factors or development 
of new, age-specific risk factors. In addition, risk factors may have synergistic effects 
conditional on age, i.e., the effect of a factor on the risk of thrombosis may be different 
in young and middle-aged populations compared with the elderly.
The interpretation of the effect of a risk factor for venous thrombosis in elderly popula-
tions is difficult as new risk factors may develop and accumulate during life. In addition, 
age-related changes of the association between a risk factors and venous thrombosis 
could be explained by the phenomenon: “attrition of susceptibles”, i.e., individuals 
highly vulnerable to a risk factor are likely to develop thrombosis early in life, resulting 
in an elderly population that is less affected by this risk factor, leading to a weakened 
association between this risk factor and the occurrence of a first venous thrombosis in 
the elderly.
Several statistical measures can be used to express the importance of a risk factor in 
the development of disease. The rate difference (Ie – I0), i.e. the difference of the incidence 
in the presence (Ie) or absence of the risk factor (I0) indicates the excess number of cases 
due to the presence of a risk factor in a certain time period. The proportion of disease 
among those with the risk factor which can be attributed to that risk factor is expressed 
as the attributable risk (AR: Ie – I0)/ Ie. A population attributable risk (PAR= (I - I0)/ I) indi-
cates what proportion of the total incidence of a disease in the general population can 
be attributed to a certain risk factor. The latter is dependent on the prevalence of the risk 
factor in the general population. While the AR is also called ‘aetiologic fraction’, the PAR 
is the ‘preventable fraction’, for it indicates for a specific population which proportion of 
the burden of a certain disease could be removed by complete removal of the risk factor.
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The role of many conventional and age specific risk factors in the explanation of the 
strong age-gradient of venous thrombosis has not before been summarised. This review 
will provide an overview of the prevalence and effect of conventional risk factors as 
well as age-specific risk factors for venous thrombosis in the older population. We will, 
wherever possible, calculate (population) attributable risks, to quantify the impact of risk 
factors on venous thrombosis and to compare the risk in young and the elderly popula-
tions. Furthermore, using available information on risk factors for venous thrombosis in 
the elderly, we will attempt to identify high-risk groups within the elderly population.
ConVentionAl risk fACtors
Table 1 shows conventional risk factors of venous thrombosis and attributable and 
population attributable risks in the young and older population are provided.
immobility
Immobility, leading to rheologic changes by increasing blood viscosity and stasis, is as-
sociated with an increased risk of venous thrombosis. [7,8] There is no single definition 
of immobility. Differences in the definition for immobilisation, and the presence of un-
derlying conditions while immobilised, such as hospitalisation because of surgery, make 
it difficult to provide one estimate of the strength of the association with thrombosis.
In a meta-analysis by Pottier et al., a pooled odds ratio (OR) of more than two was 
reported for immobilised compared with non-immobilised medical patients, not tak-
ing into account the age of the patients. [9] In hospitalised patients aged >65 years, 
table 1. Conventional risk factors of venous thrombosis: attributable and population attributable risks in 















immobilisation* 50–90 66–83 10 25 9–47 33–56
malignancy† 86 86 3 10 15 35
Chf‡ 60–71 33–60 5 22 7–11 10–25
CoPd§ 50-80 33 1 11 1–4 5
dm 50 0–50 6 16 6 0–14
hrt use** 50 50 4 1 4 1
Genetic factors†† 67–86 50–80 7 7 12–30 7–22
VT, venous thrombosis; Young, young and middle-aged population (< 65 years old); Old, older population 
(≥ 65 years old); AR, attributable risk; Prev, prevalence; PAR, population attributable risk; CHF, congestive 
heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HRT, hormone replace-
ment therapy. *Ref. [7–13,18]. †Ref. [11,19–23]. ‡Ref. [10,24–28]. §Ref. [32–34]. ¶Ref. [35–40]. **Ref. [51–62]. 
††Ref. [70–76].
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short-term bed rest (up to 14 days) was associated with an almost six-fold increase in 
thrombotic risk compared with patients without bed rest. [10] Furthermore in young 
and middle-aged populations, hospitalisation was found to contribute to venous throm-
bosis in more than half of all cases in the general population (PAR: 50%), and a 8 to 10-
fold increased risk of venous thrombosis during hospitalisation has been reported. [11] 
Surgery leads to a six-fold increased risk of venous thrombosis [12] and approximately 
three percent of individuals undergoing lower limb arthroplasty (whose average age is 
over 65) develop venous thrombosis even when they receive prophylactic medication. 
[13] The thrombotic risk associated with hospitalisation has not been studied specifi-
cally in the elderly population; however, since the prevalence of hospitalisation doubles 
with age (from ~ 10% in the population of 45 to 64 years to 25% in individuals of 65 years 
and older), the population attributable risks will be highest in the elderly. (PAR young 
~10%, PAR old: ~40%). [9-15]
Numerous other causes for immobility can be identified, e.g., plaster cast and pro-
longed travel. Lower extremity injury and plaster casts often lead to immobilisation, and 
both have been identified as strong risk factors for venous thrombosis in the young and 
middle-aged population [14]; however, they have not been studied in the elderly.
Furthermore, long-haul travel leads to short-term immobility and was associated with 
a two-fold increased risk of venous thrombosis in the young and middle aged popula-
tion in the MEGA study. [15,16] Air travel was found to affect the thrombotic risk also 
in the eldest subgroup of the study (50-71 years), but their absolute risk of thrombosis 
was lower than in the younger group. [17] The frequency of air travel is four-fold higher 
among young and middle aged than in the older population. Therefore, the population 
attributable risk will be lower in the elderly population than in the young and middle-
aged indicating that air travel contributes mainly to the overall burden of thrombosis in 
the younger population. [18]
Long-term reduced mobility predominantly affects the elderly. In the Netherlands, 
~10% of the people aged 45 to 64 years have disabilities affecting mobility, increasing 
to more than one third of the 75 years and older individuals. [19] Long-term immobility 
appears to be associated with the risk of venous thrombosis, although the risk appears 
to be strongest in the first four weeks of bed rest (3 to 4-fold increased). Similar results 
have been reported for arm chair immobilisation in a 65 years and older population. 
[10,20]
malignancy
The overall risk of venous thrombosis in cancer patients is seven-fold increased com-
pared with individuals without cancer. [11,21] This risk differs according to the type and 
location of the primary tumor, the extensiveness of the disease, and the cancer therapy. 
[22] Little information is available on the estimates of the risk of venous thrombosis 
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associated with malignancy in specifically the elderly patients. The absolute risk of ve-
nous thrombosis for ovarian cancer patients (treated with surgery and chemotherapy) 
of 61 years and older was reported to be ~250 per 1000 patients years. [23] Similar to the 
young and middle-aged population, pancreatic, ovarial and brain tumors are described 
to be associated most strongly with venous thrombosis in the elderly cancer patient. 
[4,22,24] Furthermore, cancer associated venous thrombosis is more prevalent in the 
population of 70 years and over than in a younger population. [25] This can be explained 
by the increase of the incidence of malignancy with age (i.e., three-fold increase of 
incidence for those over 65 years compared with those younger than 65 years). [19] 
As the present literature suggests that a seven-fold increased risk of development of 
thrombosis in cancer patients exists, we can conclude that the PAR is 15% in the younger 
population and 35% in the elderly.
Co-morbidity
Diseases that have been identified to affect the risk of thrombosis are, e.g., heart failure, 
stroke, chronic obstructive pulmonary disease (COPD) and diabetes mellitus. Congestive 
heart failure has been associated with a 2.5 to 3.5-fold increase of the risk of venous 
thrombosis. [26,27] This risk was mainly increased for pulmonary emboli. These risk esti-
mates were reported in studies among patients with a mean age of 60 years and older. 
In studies in which only patients older than 65 years (median 82 and 85 years) were 
included, risk estimate of ~1.5 to 2.5 were reported [10,28]. As congestive heart failure is 
> four times more prevalent in individuals of 75 years and older compared with those of 
55 to 74 years old (prevalence ~22% versus ~5%), it contributes more to the incidence of 
thrombosis in the elderly than in the middle aged population. [29-32]
Stroke increases the risk of venous thrombosis 1.3-3.5-fold in elderly inpatients (>65 
years old). The severity of stroke is positively associated with the risk of thrombosis. 
[28,33,34] The risk of venous thrombosis in younger stroke patients has not been stud-
ied. However, it is likely, as stroke is a disease of the elderly, [34,35] that the population 
attributable risk will be higher in older than in middle-aged populations.
Chronic obstructive pulmonary disease (COPD) is a risk factor for pulmonary embo-
lism and deep venous thrombosis. In individuals aged over 60, the presence of COPD 
was associated with a 1.2-1.4 increased risk of pulmonary embolism. [36,37] In a younger 
population (aged 40 to 59 years) the relative risk was higher, i.e., 2 to 5. As COPD is 
ten times more prevalent in the elderly than in the younger population (75 to 79 years: 
prevalence ~11%; 45 to 49 years 1%), population attributable risks are less than 5% for 
the overall COPD population. In the elderly population with thrombosis the highest 
contribution of COPD is expected. [19,38]
In a meta-analysis it was shown that individuals with diabetes mellitus have an 
almost 50% increased risk of venous thrombosis compared with individuals without 
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diabetes. [39] However, individual studies report contradictory results on the risk of 
thrombosis associated with diabetes, i.e., risk estimates range between no effect (RR=1) 
to a twofold increased risk for those with diabetes compared with those without the 
disease. [40-42] The risk of venous thrombosis associated with diabetes was reported 
to be higher in the younger (RR = ~2) than in the older population (RR= 1.5). [40] Since 
diabetes mellitus is more prevalent in the elderly (16% vs. 6%) than in young and middle-
aged individuals, this will indicate that the contribution of diabetes to the thrombosis 
incidence is approximately equivalent in the young and elderly population. [43,44]
Increasing age is positively associated with the prevalence of various chronic disor-
ders. The prevalence of two or more chronic diseases has been estimated at 35% in 40 
to 59 years old, and increases to almost 80% in people aged 80 and older. [45,46] Elderly 
with multi-morbidity are likely to be especially vulnerable to develop thrombosis as 
interaction of the separate effects of these risk factors may exist.
hormone replacement therapy
Hormone replacement therapy (HRT) leads to a procoagulable state, with elevated 
levels of factors VII, IX, X, XII, and FXIII and decreased levels of the anticoagulant proteins 
antithrombin and protein S. [47,48] Hormone therapy is associated with a 2 to 3-fold in-
creased risk of thrombosis in the middle-aged and elderly population. [49-54] Combined 
use of estrogen and progestin was reported to be associated with a higher thrombotic 
risk than with estrogen use only. [54] The relative risk of venous thrombosis associated 
with hormone use was similar for middle aged and elderly women, i.e., within age strata 
of 50-59 years, 60-69 years, and 70-79 years, the relative risk of venous thrombosis for 
hormone users was two-fold increased compared with non-use [55,56]. The publication 
of studies reporting an increased risk of complications associated with hormone use, 
e.g. breast cancer, led to a more than 50% decrease in the use of post-menopausal 
hormones. [57] In the Netherlands, HRT is used predominantly by middle aged women, 
and less so in the elderly, i.e., HRT use in 2004 was 4% in women aged 50 to 54 years 
and 1% in women aged 70 to 74 years. [58] Therefore, while HRT use is associated with a 
similar relative risk of thrombosis in the elderly compared with middle aged women, it is 
associated with a lower population attributable risk in the elderly due to its scarce use.
haemostasis factors
Elevated levels of D-dimer, homocysteine, von Willebrand Factor (vWF) and coagulation 
factors, FVIII, FIX, FXI, fibrinogen, and prothrombin are all associated with increased risks 
of venous thrombosis, with roughly a doubling of the risk for those with a coagulation 
factor level in the upper 10 percent (P90) of the population distribution of levels. [59-63] 
With increasing age plasma levels of many haemostatic factors are also increasing e.g., 
fibrinogen, FVIII, FVII, d-dimer and homocysteine. [60,64]
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Scarce data are present comparing high and low levels of haemostatic factors in the 
elderly and their associated risk of venous thrombosis. Thus far, for high FVIII and VWF 
levels an increased risk of thrombosis in the elderly has been reported (2 to 3-fold) [62]. 
However, the association between high fibrinogen levels and the risk of venous throm-
bosis is still controversial. [62,65]
Cut-off points used in young and middle-aged populations for low and high levels 
in young individuals are difficult to interpret within the older population. Therefore, 
population attributable risks are not provided.
Genetic risk factors
The most common genetic risk factors for venous thrombosis are the prothrom-
botic mutations factor V Leiden (FVL, rs6025) and the prothrombin 20210A mutation 
(PT20210, rs1799963). The prevalence of these genetic variants are similar in the young 
and elderly. [66-68] However, they vary widely between ethnic groups The factor V 
Leiden mutation increases the risk of venous thrombosis three to seven-fold in individu-
als younger than 70 years compared with non-carriers. [69-71] This mutation has also 
been associated with an increased risk of thrombosis in the elderly, i.e., in individuals 
over 60 years a five-fold increased risk of thrombosis has been reported. [72] Studies in 
the elderly population found a 1.5 to 4.5-fold increased risk of thrombosis for carriers of 
the PT20210A mutation as compared with wild type carriers. [73,74] Thus, the factor V 
Leiden and the PT20210A mutation increase the risk of thrombosis 2 to 5-fold, and their 
prevalence is 7%. This implies that these two mutations are responsible for ~25% of all 
thromboses (PAR), regardless of age.
AGe-sPeCifiC risk fACtors
Age-specific factors are factors that are almost exclusively present in the older popula-
tion. Although not studied in great detail yet, we can speculate that these factors are 
likely to explain at least partly, the steep age gradient in the risk of venous thrombosis.
muscle strength
The overall muscle strength declines with age starting from the age of 50 years. [75] It 
is likely that this also affects the calf muscle pump. Indeed, it has been reported that 
both the calf compliance and the capacitance response, a marker for the redistribution 
of peripheral venous blood to the central circulation, decline over time. [76] Although 
the role of muscle strength of the lower limbs and the concomitant deterioration in the 
venous hemodynamics is not yet clarified, diminished function or efficacy of the calf 
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muscle pump could lead to reflux and stasis, which subsequently may lead to thrombus 
formation.
endothelial dysfunction
Endothelial dysfunction is the alteration of the actions of the endothelium toward 
reduced vasodilation, and more prothrombic properties. Endothelial dysfunction is an 
important age-associated cardiovascular phenomenon. [77] With increasing age the 
anatomy of the venous vessel wall is modified, e.g., muscle fibers atrophy and valves 
thicken by an increase the number of collagen fibers. [78] Moreover, ageing has been 
associated with as shift towards less anticoagulant properties of the endothelium, i.e., it 
has been suggested that endothelial thrombo-resistance in the valves diminishes with 
age. [79] In addition, changes in laminar shear stress that for example occurs in varicose 
veins could diminish the release of anti-inflammatory and anticoagulant factors. [80] 
Hence, remodeling of the venous vessel wall with increasing age may contribute to 
the age gradient in the risk of thrombosis. The finding of an increased risk of venous 
thrombosis associated with microalbuminuria which may be a reflection of endothelial 
dysfunction strengthens this hypothesis. [81]
Venous insufficiency
The pathophysiology of chronic venous insufficiency consists of failure of valves through 
dilation of the venous wall or remodelling of the valve leaflets, which subsequently 
can lead to stasis and elevation of distal venous blood pressure. The prevalence of this 
functional disease increases with age. [82,83] Histological findings associated with 
venous insufficiency are increased collagen content of the vessel wall and disruption 
of the smooth muscle cells and elastic fibers. Currently it is unknown whether venous 
insufficiency is associated with an increased risk of thrombosis in the elderly.
AGe sPeCifiC risk GrouPs
Venous thrombosis is a multicausal disease, i.e., more then one risk factor needs to be 
present simultaneously to cause the disease. Especially in the elderly risk factors are 
likely to accumulate. Therefore, high risk-profiles may often be present in the elderly, 
which may be specifically of interest when considering preventive measures, e.g., pro-
phylactic treatment with anticoagulants.
female sex
Women have a higher life expectancy than men, leading to a sex-ratio in favour of 
women in the elderly population. [5] As no sex-difference is reported for the risk of 
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thrombosis in the general population, this will lead to a higher proportion of women 
among elderly patients with venous thrombosis. Interest should therefore focus on risk 
factors for venous thrombosis with a high prevalence in women. These are likely to be of 
great importance in the explanation of the age gradient of the risk of venous thrombosis.
nursing home
In the Netherlands, approximately 6% of the people of 65 years and older are institu-
tionalised and half of the residents of these institutions are 85 years and older. [84] It 
was reported that living in a nursing home increased the risk of venous thrombosis 
eight-fold as compared with similarly aged individuals not institutionalised. [85] An 
incidence of venous thrombosis of 13 events per 1000 py was reported in nursing home 
residents. [86] However risk estimates are not yet reported for this specific group. The 
potential high risk of venous thrombosis in nursing homes would likely be the result 
of a high prevalence of other risk factors discussed before, e.g., immobilisation and co-
morbidities.
frailty
Buchner and Wagner defined the concept of frailty as “losses of physiologic reserve 
that increase the risk of disability” [87]. Many indices are used to objectify frailty. Most 
commonly deficits in health including restricted activity, disability in activities of daily 
living (ADL), and impairments in general cognition and physical performance are taken 
into account. Additionally, co-morbidity and self-rated health are often measured. It was 
shown that the percentage of individuals with frailty increases with age, from less than 
4% in the 65-74 years old group to 25% in the 85 years and older age group, and the frail 
group appeared to have a 30% increased risk to develop venous thrombosis compared 
with the no-frailty. [88]
ConClusion
Despite the clear age gradient in the risk of venous thrombosis, limited data are avail-
able on risk factors for venous thrombosis in the age group that is mostly affected by the 
disease, i.e., the elderly population. Therefore, the risk estimates provided in this review 
are mostly based on small study groups and subgroup analyses.
Many conventional risk factors for venous thrombosis established in the young and 
middle-aged population are likely to also increase the risk of thrombosis in the elderly. 
Immobility, malignant disease, co-morbidities, and increased levels of coagulation fac-
tors remain associated with an increased risk of thrombosis in the elderly population. 
Furthermore, common genetic risk factors, e.g., the factor V Leiden and the prothrombin 
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20210A mutation are also associated with thrombotic risk in the elderly, although lower 
risk estimates as compared with the younger population were reported.
We found that many of the conventional risk factors such as, immobilisation, malig-
nant diseases and co-morbidities are more prevalent in the elderly than in young and 
middle-aged individuals. The risk factors that contribute highly to the increased inci-
dence of venous thrombosis in the elderly (i.e., with the highest PAR), are immobilisation 
and the genetic risk factors. We found that immobilisation contributes to more than 
40% off all venous thrombotic events, and genetic factors explain between 7 to 22 % 
of the thrombotic events. Thrombotic risk factors that appear to contribute less in the 
incidence of thrombosis in the elderly are long haul travelling and the use of hormone 
replacement therapy.
We hypothesise that age-specific risk factors of venous thrombosis such as endothelial 
dysfunction and venous insufficiency in the elderly could in part clarify the strong age 
gradient of thrombosis. This also includes factors as frailty and institutionalised living.
The strong age-gradient in the risk of venous thrombosis has led to numerous reports 
on the association between risk factors and thrombosis in the elderly, however only 
in very small subgroups. Subsequently, only limited conclusions can be drawn. We 
speculated about the different factors that may play a role in the development of ve-
nous thrombosis and their role in the incidence gradient with ageing, though research 
specified on the most affected, older population is necessary to draw firm conclusions. 
Moreover, high risk groups need to be identified, in order to be able to target preventive 
measures such as prophylactic treatment with anticoagulants to high risk groups. This 
may result in the prevention of life-threatening side effects of this treatment such as 
major bleeding. In addition, complications and morbidities after a venous thrombotic 
event need to be evaluated in this potentially more vulnerable population.
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Venous thrombosis is common in the older population. Assessment of risk factors is 
necessary in order to implement preventive measures.
objectives
We studied the associations between immobility-related risk factors and thrombosis, 
specifically, hospitalisation, surgery, fractures, plaster cast use, minor injuries, and tran-
sient immobility at home in an older population.
methods
Analyses were performed in the Age and Thrombosis, Acquired and Genetic risk factors 
in the Elderly (AT-AGE) study, a two-centre population-based case-control study. Con-
secutive cases aged ≥70 years with a first-time thrombosis (n= 401) and control subjects 
≥70 years old without a history of thrombosis were included (n= 431). Exclusion criteria 
were active malignancy and severe cognitive disorders. We calculated odds ratios (OR) 
with 95% confidence intervals (CI95) after adjustment for age, sex, body mass index and 
study centre, and population attributable risks (PAR).
results
There was a 15-fold (OR 14.8; CI95 4.4-50.4) increased risk of thrombosis within two 
weeks after hospital discharge. Surgery (OR 6.6; CI95 3.7-11.6), fractures (OR 12.7; CI95 
3.7-43.7), plaster cast (OR 6.2; CI95 2.0-18.9), minor leg injuries (OR 1.9; CI95 1.1-3.3), and 
transient immobility at home (OR 5.0; CI95 2.3-11.2) were all associated with thrombosis 
risk over three months. The PAR for in-hospital immobility was 27%, and for out-of-
hospital immobility 15%.
Conclusions
In those over 70 years of age, in-hospital and out-of hospital immobility are strong risk 
factors for thrombosis. Additional studies on preventive measures during immobilisa-
tion in this age group should not focus solely on hospital settings.
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introduCtion
Venous thrombosis presents mainly as deep venous thrombosis of the leg (DVT) and 
pulmonary embolism (PE). The incidence of thrombosis increases sharply with age, being 
rare in young individuals (<1 per 10 000 per year) and increasing to approximately 1% 
per year in very old age. [1] More than two thirds of all patients with venous thrombosis 
are aged 60 years and older, and 25% are older than 80 years. [2] So, increasing age is one 
of the most important risk factors. As venous thrombosis is a potentially lethal disease, 
morbidity (e.g. the post thrombotic syndrome) is common, and treatment has frequent 
side effects, prevention efforts will have large effects in older individuals. [3] However, 
the risk factors for thrombosis in the older population are not well characterised since 
studies to date mainly included young and middle aged individuals. [4]
Immobility is associated with reduced venous blood flow, particularly in the pockets 
of the venous valves, leading to inflammation and hypercoagulability. [5,6] In young 
and middle-aged individuals, immobility, for example due to hospitalisation or minor 
injuries, is an established risk factor for thrombosis with relative risk estimates ranging 
from 3 to 11. [7,8] However, it is unknown to what extent immobilisation increases the 
risk of venous thrombosis in older individuals. We hypothesised that immobility-related 
risk factors would be strong risk factors in this population.
The aim of this study was to assess the risk of venous thrombosis associated with 
hospitalisation, surgery, use of a plaster cast, minor injury, and transient immobility at 
home in a case-control study of people aged 70 years and older.
methods
identification of participants
The Age and Thrombosis, Acquired and Genetic risk factors in the Elderly (AT-AGE) Study 
is a two-centre, population based case-control study in Leiden, the Netherlands and 
Burlington, Vermont, US, designed to study risk factors for venous thrombosis in the 
older population. From June 2008 to August 2011 in Leiden and December 2008 to July 
2011 in Vermont, all consecutive patients 70 years and older with DVT or PE were identi-
fied.
In Leiden, cases were identified from two anticoagulation clinics in a defined geo-
graphical area in the western part of the Netherlands. In Vermont, cases were identified 
in the Vascular Laboratory and the Radiology department of the University of Vermont 
Medical Centre in Burlington, Vermont, which are the only diagnostic centres in that 
geographic area. We defined venous thrombosis as DVT alone or PE with or without 
a proven DVT by ultrasound (PE±DVT). We were unable to accurately define isolated 
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PE without DVT since diagnostic measures of thrombosis of the legs are not routinely 
performed in all PE patients. Control subjects were identified in Leiden and Vermont in 
the same geographical area as the cases. Control subjects were randomly selected from 
five primary care practices in Leiden and four in Vermont.
All identified cases and control subjects were mailed an invitation letter, followed by 
a telephone call to discuss participation. Individuals were excluded from participation if 
they responded affirmatively that they had an active malignancy, defined as diagnosis of 
cancer within six months before the thrombotic event (or date of telephone call for the 
control subjects) or chemotherapy or radiation therapy for cancer in the last six months. 
Potential participants with severe psychiatric or cognitive disorder, as judged by the 
telephone contact, were excluded. We also excluded individuals who self-reported 
previous DVT or PE within the past 10 years.
Of the 1187 identified cases, 689 (58%) were eligible and 498 (42%) were excluded. 
(figure 1) Of those excluded, 55 (11%) died before inclusion was possible, 159 (32%) had 
active malignancy, 108 (22%) had an apparent severe cognitive or psychiatric disorder, 
and 171 (34%) had a history of venous thrombosis within the last 10 years. Of the 723 
identified control subjects, 631 (87%) were eligible and 92 (13%) were excluded: 15 
(16%) died before inclusion was possible, 19 (21%) had active malignancy, 34 (37%) 
had an apparent severe cognitive or psychiatric disorder and 10 (11%) had a history of 
venous thrombosis within the last 10 years (see figure 2 for participation flowchart by 
study centre).
All participants provided written informed consent in accordance with the Declaration 
of Helsinki and gave permission to obtain information about their medical history. The 
study was approved by the Medical Ethical Committee of the Leiden University Medical 
Centre and by the Committee of Human Research of the University of Vermont.
data collection
In Leiden, 398 (71%) of the 561 invited cases and 321 (76%) of the 422 invited control 
subjects participated. In Vermont, 128 cases were invited and 75 (59%) participated, 
while 140 (67%) of the 209 invited control subjects participated. For all eligible cases and 
controls subjects who agreed to participate, home visits were scheduled. During this 
home visit, an extensive structured interview and blood collection was completed by 
trained personnel. The index date was defined as the date of diagnosis of the thrombosis 
for the cases and the date of the in home interview for the control subjects.
The interview assessed thrombosis risk factors that have been established in the 
young and middle-aged as well as other putative age-specific risk factors that were 
present within 3 months of the index date. Questions queried hospitalisations, surgery 
during hospitalisation, fractures and use of plaster cast (or splint), minor injuries of 
the lower extremities and transient immobility at home, including dates and location. 
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Physical measurements were performed including weight (measured with a calibrated 
scale) and height. Body mass index (BMI) was calculated by dividing body weight (kg) 
by squared height (m2).
Analyses
For these analyses on the etiology of thrombosis we included only cases and control 
subjects without a history of venous thrombosis (403 cases and 433 control subjects) 
who had complete interview data (401 cases and 431 control subjects). Characteristics 
of the control subjects included in Leiden and in Vermont were analysed separately to 
provide insight into the source populations. For all further analyses, we combined data 
from the two sites. We determined associations between transient immobility-related 
risk factors and venous thrombosis. Transient immobility was defined as a status of im-
mobility that is shortly present in one’s life. As estimates of relative risk, we calculated 
odds ratios (OR) and their 95% confidence intervals (CI95) using logistic regression 
models. All reported ORs were adjusted for age (continuous), sex, BMI (continuous) and 
study centre using multivariable logistic regression analysis. Stratified analyses were 
performed for DVT and for PE±DVT.
Hospitalisation was defined as present when the participant was hospitalised at the 
index date or the discharge date was within the three months window previous to the 
figure 1. Flowchart of AT-AGE study
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figure 2. Flowchart of AT-AGE study per center
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index date. Hospital admission for both in-patients and day patients were taken into ac-
count. Hospitalisation for surgical and non-surgical indications was analysed separately. 
The presence of a fracture or plaster cast (or splint) in the three months before the index 
date were analysed as putative risk factors as were minor injuries of the lower extremi-
ties and transient immobility at home. A minor injury was defined as an injury of the 
lower extremities (hip, knee, ankle or foot) such as a sprained ankle or contusion of the 
lower leg that started within the three months window. A period of transient immobility 
at home was defined as a period of four or more consecutive days of immobility, such as 
being bedridden or continuously sitting in a chair, that started within the three months 
before the index date.
If participants were bed- or chair-ridden for the entire three months prior to the index 
date they were classified as chronically immobilised and not included in these analyses. 
To study duration of risk of venous thrombosis after the transient risk factor, we dichot-
omised the time between the risk factor and venous thrombosis by the median time 
from the end of the risk period (for hospitalisation) or the start of the risk period (for 
minor injury or transient immobility at home) in the control subjects. Since the group of 
table 1. Characteristics of control subjects by center
Controls nl Controls Vt
306 125
median Age, n (range) 76 (70-94) 76 (70-96)
 70-75 years, n (%)
 75-80 years, n (%)
 80-85 years, n (%)









men, n (%) 147 (48) 62 (50)
ethnicity White, n (%)* 284 (93) 124 (99)
smoking status*
 Never, n (%)
 Former, n (%)







median bmi (kg.m-2) (range) * 25.9 (17.0-42.0) 27.3 (19.0-49.7)
hospitalisation, n (%)† 16 (5) 13 (10)
surgery, n (%)† 12 (4) 4 (3)
fracture, n (%)† 1 (0.3) 2 (2)
Plaster cast (splint), n (%)† 2 (1) 2 (2)
minor injury, n (%)*† 18 (6) 8 (7)
transient immobility at home, n (%)*† 5 (2) 3 (2)
NL= the Netherlands, VT= Vermont, n = number, BMI = Body Mass Index.
* ethnicity 5 missings, smoking 1 missings, BMI 8 missings, minor injury 1 missing, transient immobility at 
home 1 missing
† < three months before index date
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participants with hospitalisation in the three months prior to the index date was large 
enough for further stratification, to study the time trend in risk of venous thrombosis 
in more detail, the time after hospital discharge was divided into three periods (< two 
weeks, two-four weeks, four weeks-three months). The small number of control subjects 
with fractures or plaster cast prohibited a detailed analysis of the risk by time from im-
mobilisation.
In addition, sensitivity analyses were performed. Since the index date was defined as 
the date of the home visit for the control subjects and therefore, per definition, none of 
the controls was hospitalised on the index date, assessment of the risk of thrombosis 
during hospitalisation was not directly possible. To estimate the risk of venous thrombo-
sis during hospitalisation, the index date of the controls was moved back by five weeks, 
i.e, by the median time (in weeks) of the cases between diagnosis of thrombosis and 
home visit.
We calculated population attributable risk (PAR) as: pd (OR-1)/(OR); in which pd is the 
proportion of cases exposed to the risk factor of interest. In this case the PAR indicates 
the proportion of the total incidence of venous thrombosis in those 70 and older who 
were eligible for this study that can be attributed to the risk factor of interest. [9,10] We 
calculated the PAR for all immobility related risk factors combined, and for in-hospital 










 surgery, n (%)†
thrombosis after discharge, n (%)
 time after discharge‡
  < 2 weeks (%)
  2-4 weeks (%)






















fracture, n (%)† 27 (6.7) 3 (0.7) 10.3 (3.1-34.2) 12.7 (3.7-43.7)
Plaster cast (splint), n (%)† 21 (5.2) 4 (0.9) 5.9 (2.0-17.3) 6.2 (2.0-18.9)
minor injury, n (%)†‡
 start of minor injury~
  < 4 weeks (%)













transient immobility at home, n (%)†‡
 start of transient immobility‡
  < 9 weeks (%)













n = number, OR = oddsratio, CI = confidence interval.
*adjusted for age (continuous), sex, BMI: body mass index (continuous) and study center.
† < three months before index date
‡ time after discharge: cases: 1 missings, controls 1 missings; minor injury 6 missings, transient immobility 
at home: 6 missings
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and out-of-hospital immobility, separately. Out-of-hospital immobility was defined as 
the presence of fractures, plaster cast (or splint), minor injuries, and transient immobility 
at home within the non-hospitalised population.
results
For the cases, the median duration between the index date and the home visit was five 
weeks (range 1-44 weeks), 75% were visited within seven weeks, and 90% within 10 
weeks. General characteristics of the control subjects in Leiden and Vermont are shown 
in table 1. In both centres, ~30% of the control subjects were 80 years and older. Median 
BMI was slightly higher in Vermont than Leiden. Of the 401 cases, in Leiden, 134 (39%) 
of the cases had DVT, and 207 (61%) had PE±DVT, and in Vermont 32 (53%) had DVT 
and 28 (47%) PE±DVT. In 155 of the 166 DVT cases (93%), and in 220/235 of the PE cases 
(94%) we were able to obtain the diagnostic report of the thrombotic event, and was the 
thrombosis thus objectively confirmed by ultrasound and PE was confirmed by spiral 
computed tomography or ventilation-perfusion lung scan.
Table 2 shows the risk of venous thrombosis associated with immobility-related risk 
factors. Overall, hospitalisation was associated with a more than 7-fold increased risk 
of venous thrombosis (OR = 7.2, CI95 4.5-11.4). Among cases and controls with hospi-
talisation, the median duration of hospital stay in the cases was 10 days (range 2-55) 
and in the control subjects 3 days (range 1-22). Dichotomisation of the time between 
discharge from hospital and the index date, based on the median time of hospitalisation 
until the index date in the control subject (48 days, range 4-89) showed that the risk 
of venous thrombosis was 7.9-fold increased in the first seven weeks after discharge 
(OR 7.9; CI95 4.2-14.7) and 2.1-fold increased after seven weeks (7 weeks- 3 months, OR 
2.1; CI95 1.0-4.4). Further stratification of the time between hospital discharge and the 
table 3. Odds ratios of thrombosis over three months with transient immobility risk factors stratified by 
type of thrombosis
exposure n, dVt/total Vt (%) dVt or (Ci95)* Pe±dVt or (Ci95)*
hospitalisation 43/126 (34) 5.6 (3.2-9-8) 9.1 (5.5-15.2)
surgery 27/79 (34) 5.3 (2.7-10.4) 7.9 (4.2-14.6)
fracture 11/27 (41) 14.2 (3.7-55.3) 10.9 (2.9-40.5)
Plaster cast (splint) 6/21 (29) 4.2 (1.1-16.5) 7.6 (2.3-24.9)
minor injury 24/41 (59) 2.6 (1.4-4.9) 1.4 (0.7-2.6)
transient immobility at home 7/34 (21) 2.4 (0.8-6.8) 7.4 (3.2-17.2)
N= number, VT = venous thrombosis, DVT= deep venous thrombosis of the leg, PE = pulmonary embolism, 
OR = odds ratio, CI = confidence interval.
*adjusted for age (continuous), sex, BMI: body mass index (continuous) and study center.
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index date showed a 14.8-fold increased risk of thrombosis within the first two weeks 
after discharge from the hospital (OR 14.8; CI95 4.4-50.4) and gradually decreasing risk 
to a 3-fold increased risk between four weeks and three months after discharge (table 
2). Performing a sensitivity analysis using the recalculated index date for the controls, 
41 (10.1%) cases and 1 (0.2%) control subject was hospitalised during the index date 
indicating that the thrombotic risk was highest during hospitalisation although the 
confidence interval was wide (OR 48.7; CI95 6.6-361.0).
Among the cases hospitalised within the three months prior to the index date, 79 of the 
126 (63%) had surgery during the hospital admission. When compared with individuals 
without hospitalisation, the risk of venous thrombosis associated with surgery-related 
hospitalisations (OR 6.6, CI95 3.7-11.6) was similar to non-surgery hospitalisations (OR 
5.5 CI95 2.7-10.4) (OR for surgical versus non-surgical admission = 1.1, CI95 0.4-2.7). 
Thirty-one (7.8%) of the cases and 4 (0.9%) of the control subjects underwent lower ex-
tremity surgery, indicating that lower extremity surgery was associated with an almost 
9-fold increased risk of thrombosis (OR = 8.6, CI95 3.0-25.1).
Fracture was associated with a nearly 13-fold increased risk of thrombosis (OR 12.7, 
CI95 3.7-43.7). In the cases, two-thirds of fractures (n=17) were of the lower extremities 
of which 8 (47%) presented with a DVT. In 87% of these cases the DVT was diagnosed on 
the ipsilateral side as the fracture. Use of a plaster cast or a splint was associated with a 
6-fold increased risk of thrombosis (OR= 6.2; CI95 2.0- 18.9).
Minor leg injury was associated with a 1.9-fold increased risk of thrombosis (OR = 1.9; 
CI95 1.1- 3.3). The median time of occurrence of the minor injury until the index date was 
43 days (range 1-92) for the cases and 27 days (range 4-93) for the controls. Compared 
with individuals without a minor injury in the three months prior to the index date, the 
risk of venous thrombosis was 1.3-fold (CI95 0.6-2.7) increased in the first 4 weeks after 
start of the minor injury and remained 2.8-fold (CI95 1.3-5.8) increased between four 
weeks and three months after the start of the immobility. The risk of thrombosis was 
increased in individuals with sprains of the ankle or knee (OR 1.9; CI95 0.6-6.1) and a 
contusion of the leg (OR 1.5; CI95 0.7-3.1). In 24 of the 41 cases (59%) with a minor injury 
a DVT was diagnosed, while 17 cases (41%) had PE±DVT. In 22 of these 24 cases (92%) 
the DVT was diagnosed on the ipsilateral side as the minor injury.
Transient immobilisation was associated with a 5-fold increased risk of thrombosis 
(OR = 5.0, CI95 2.3- 11.2). Median duration of transient immobilisation at home in the 
cases was 8 days (range 4-77 days) and 10 days (range 4-30 days) in control subjects. 
The median time of the start of transient immobility until the index date, was 27 days 
(range 2-81) for the cases, and 63 days (range 38-86) for the control subjects. The risk of 
thrombosis was 7.7-fold increased (CI95 2.6-22.9) within the first 9 weeks (63 days) after 
the transient immobility, whereas as an OR of 2.5 (CI95 0.8-8.5) was found if transient im-
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mobility was more than 9 weeks up to 3 months previous. In 42% of the cases the reason 
for transient immobilisation at home was an infection, 23% had generalised weakness or 
“malaise”, 17% had fracture, and 9% each had back pain or a minor injury. Of the cases, 5 
(1.2%) were chronically immobilised, whereas none of the control subjects were.
All immobility risk factors were similarly associated with both DVT and PE±DVT. (Table 
3) Overall, immobilisation from any cause had a PAR of 39%. In-hospital immobility and 
out-of-hospital immobility had population attributable risks of 27% and 15%, respec-
tively.
disCussion
In the AT-AGE study, a case-control study on venous thrombosis risk in people aged 
70 years and older, we determined that immobility-related risk factors, i.e., hospitalisa-
tion, surgery, fractures, plaster cast (or splint), minor injuries of the legs, and transient 
immobility at home were strongly associated with the risk of venous thrombosis (both 
DVT and PE±DVT) in the 3 months after the start of the immobility (ORs ranging be-
tween 2 and 13). The highest risk of thrombosis was for found for immobilisation during 
hospitalisation (OR 48.7; CI95 6.6-361.0), and the risk of thrombosis out-of hospital was 
15-fold increased within the two weeks after hospital discharge, and the risk remained 
increased for 3 months after hospital discharge. Predefined potential confounders of 
the risk factors, i.e, age, sex, BMI, and study centre, did not alter any of the associations. 
Previous studies on immobility and the risk of thrombosis in older populations reported 
similar risk estimates, ranging from 1.5 up to more than 8-fold increased risks. [4] Based 
on the PARs we observed, the overall contribution of immobility to thrombotic risk (both 
in and out of hospital) in this study population was 40%. A PAR of 27% was found for 
in-hospital related immobility. This contrasts with data previously reported for younger 
people, where the PAR was only 15% for hospital-related immobility. [4] Importantly, 
the PAR was 15% for out-of-hospital immobility in the last three months in this older 
population. These findings indicate that immobility explains part of the age gradient in 
the incidence of venous thrombosis.
Findings illustrate the large impact of immobility, a common occurrence in the older 
population. The prevalence of immobility related risk factors in the three months prior 
to the index date for our control group ranged from 2-8% for the different exposures.
Hospitalisation causes immobilisation. [11] In line with this we found that cases were 
hospitalised for a longer period than the control subjects. One should take into account 
that severity and disease entity during hospitalisation can influence the risk of thrombo-
sis, as can the duration of hospitalisation. [12]
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As in a younger population, we found that minor injuries were associated with a 
higher risk of thrombosis over three months. [8] For minor injury the time of highest 
risk differed than for other types of immobility, with a higher risk after four weeks com-
pared to shortly after the minor injury. For the other studied factors the risk was highest 
shortly after the exposure of immobility. It is possible that the seriousness of the minor 
injury, and the long term consequences, leading to more or less immobility, increase 
the thrombotic risk, rather than the minor injury itself. It is also possible this finding 
was a chance finding. Transient immobilisation at home increased the risk of thrombosis 
5-fold, and this risk was highest in the first two months after immobilisation. Transient 
immobilisation at home was most frequently due to infection, an important trigger for 
thrombosis. [13]
The increased risk of thrombosis associated with out-of-hospital immobility indicates 
that prophylaxis may be beneficial. Home treatment with prophylaxis has effectively 
been implemented in other high risk groups, such as orthopedic surgical patients. [14] 
The EXCLAIM trial showed a beneficial effect of a longer duration of treatment within 
the older population (>75 years). [15] However, in two clinical trials including inpatients, 
extended thromboprophylaxis after discharge reduced thrombosis rates at the cost of 
higher bleeding rates (30 days event rate: 0.5-0.8%). [16,17] Other preventive measures 
that might be considered in this high risk group include the use of graded elastic com-
pression stockings or aspirin. [18,19]
Recruiting older individuals in research is challenging. [20] We overcame this by per-
forming home visits to assess the presence of risk factors. This enabled us to recruit less 
mobile individuals and achieve a high participation rate (participation rate: cases 68%, 
control subjects 73%). As in any case-control study, recall bias might have occurred. 
However, both cases and controls were interviewed by trained personnel using a stan-
dardised interview, which minimises the risk of bias. Using an interview for assessment 
of risk factors for thrombosis within three months before the index date enabled us to 
determine putative risk factors, such as transient immobility at home, that might be 
challenging to determine, e.g., as these are not mentioned regularly in medical reports 
and they might be difficult to recall precisely after a longer period. Unfortunately, data 
on preventive measures in the hospital (e.g., low molecular heparin injections) were not 
collected. However, individuals with in-hospital immobilisation were most likely more 
often treated with thromboprophylaxis as their risk of venous thrombosis is thought to 
be increased. More frequent treatment with thromboprophylaxis in immobilised indi-
viduals compared with individuals who are not immobilised, leads to an underestimation 
of the true relative risk of venous thrombosis associated with in-hospital immobilisation.
In a case-control study, associations may be biased if the willingness to participate is 
affected by the presence of the risk factor. We minimised this bias by performing home 
visits, and achieving a high participation.
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Moreover, the sensitivity analysis in which we recalculated the index date of the con-
trol subjects, did not alter interpretations of our results. We excluded cancer patients 
so our results are not generalisable to these individuals. Finally, a number of potential 
participants died before they could be invited to participate. The impact on our results 
is difficult to determine, but these participants were more likely immobilised, resulting 
in an underestimation of the true risk.
In conclusion, the contribution of immobility-related risk factors, defined as hospitali-
sation, fracture, plaster cast (or splint), minor injury of the leg, and transient immobilisa-
tion at home to the risk of venous thrombosis in the older population is high. Studies 
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As the incidence of venous thrombosis increases strongly with age and the number of 
older people is on the rise, the focus on the older people becomes more relevant. We 
aimed to assess whether common genetic risk factors, i.e., the factor V Leiden (FVL) and 
prothrombin G20210A variants (PT), and non-O blood group, as well as a positive family 
history of venous thrombosis are risk factors for a first venous thrombosis at an older 
age (≥70 years).
methods
401 consecutive cases with a first-time thrombosis and 431 control subjects were in-
cluded in the AT-AGE case-control study. All subjects were ≥70 years. Information on risk 
factors for thrombosis, including family history, was obtained from questionnaires. Un-
provoked thrombosis was defined as thrombosis not related to surgery, fracture, plaster 
cast, minor injuries or immobility within three months prior to the venous thrombotic 
event. FVL and PT were determined in 394 cases and 426 control subjects. The risk of 
thrombosis was assessed by calculating odds ratios (OR) with 95% confidence intervals 
(CI95) after adjustment for age, sex, and study centre.
results
The risk of venous thrombosis was 2.2-fold increased in FVL carriers (CI95 1.2-3.9). This 
risk was 1.4-fold increased in PT mutation carriers (CI95 0.5-3.9). A positive family history 
was associated with a 2.1-fold increased risk of thrombosis (CI95 1.5-3.1). The OR for 
non-O blood group was 1.3 (CI95 1.0-1.8). The highest risk of thrombosis was found in 
individuals who had both a positive family history and were carriers of one of the two 
prothrombotic variants.
Conclusion
Factor V Leiden, prothrombin G20210A mutation, non-O blood group and a positive 
family history for venous thrombosis were risk factors of venous thrombosis in older 
people.
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introduCtion
Venous thrombosis is a multicausal disease, associated with both environmental and 
genetic risk factors. [1] Factor V Leiden (rs6025) and the prothrombin G20210A muta-
tion (rs1799963) are the most common prothrombotic variants (prevalence of 3-5%) in 
young and middle aged population and are associated with a 3-7-fold increase in the 
risk of venous thrombosis compared with non-carriers. [2,3] Another genetically deter-
mined risk factor, i.e., the non-O blood group, is an important determinant of venous 
and arterial disease. [4,5] In the young and middle aged population, blood group non-O 
is associated with a doubling in risk of thrombosis. [6] Aggregation of venous throm-
bosis cases in a family may reflect the presence of known and unknown genetic risk 
factors. However, conflicting results are published regarding a positive family history as 
a predictor for the presence of inherited thrombophilia. [7-10]
Most epidemiological studies include only young and middle-aged individuals. Older 
people are often excluded from clinical studies into aetiology and management because 
of co-morbidities, short life expectancies, and logistical difficulties. [11,12] Limited infor-
mation is available regarding genetic risk factors for venous thrombosis in older people. 
Furthermore, it is unknown whether a positive family history of venous thrombosis is 
predictive of a venous thrombotic event at an older age. As the incidence of venous 
thrombosis increases strongly with age and the number of older people is on the rise, 
the focus on older people becomes more relevant. Venous thrombosis is rare in young 
individuals (<1 per 10 000 per year under the age of 18) but increases to nearly 1% per 
year at very old age. [13-14]
This study aimed to assess whether common genetic risk factors, i.e., the factor V 
Leiden and prothrombin G20210A variants, and non-O blood group, as well as a positive 
family history of venous thrombosis are risk factors for a first venous thrombosis at an 
older age (≥70 years).
methods
study population and data collection
The Age and Thrombosis, Acquired and Genetic risk factors in the Elderly (AT-AGE) study 
is a two-centre, population-based case-control study designed to study risk factors for 
venous thrombosis in older people. The design of the AT-AGE study was described in 
detail previously. [15] From June 2008 to August 2011 in Leiden, the Netherlands and 
December 2008 to July 2011 in Vermont, US, all consecutive cases 70 years and older 
with a first deep venous thrombosis of the leg (DVT) or pulmonary embolism (PE) were 
identified. Cases were identified from the anticoagulation clinics in Haarlem and Leiden 
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and from the Vascular Laboratory and the Radiology department of the University of 
Vermont Medical Centre (Burlington, Vermont, United States). Control subjects were ran-
domly selected from five primary care practices in Leiden and four in Vermont. Subjects 
with an active malignancy or severe psychiatric or cognitive disorder were excluded. For 
all participants, a home visit took place, during which an extensive structured interview 
was completed by trained personnel and a blood sample or buccal swab was collected. 
The index date was defined as the date of diagnosis of the thrombosis for the cases 
and the date of the home visit for the control subjects. All participants provided writ-
ten informed consent. The study was approved by the Medical Ethical Committee of 
the Leiden University Medical Centre and by the Committee of Human Research of the 
University of Vermont.
risk factor assessment
Self-reported information on the presence of first-degree relatives (parent, sibling, or 
offspring) who experienced venous thrombosis was obtained via the interview. Family 
history of venous thrombosis was considered positive if at least one first degree relative 
experienced thrombosis. Participants who indicated that they did not know whether 
a first degree relative has had venous thrombosis were classified as having a negative 
history.
Provoked venous thrombosis was defined as thrombosis after hospitalisation, fracture, 
plaster cast, splint, minor injuries of the lower extremities (such as a sprained ankle or 
contusion of the lower leg) or transient immobility at home ≥4 successive days in the 
three months before the index date.
During the home visits, blood samples were drawn into vacuum tubes containing 
0.1-volume 0.106-mol/L trisodium citrate or when no blood sample could be drawn a 
buccal swab was collected (N=28). The blood sample was separated into plasma and 
cells through centrifugation. DNA analysis for the factor V Leiden mutation (rs6025) 
and the prothrombin G20210A mutation (rs1799963) was performed using a combined 
polymerase chain reaction method with the TaqMan assay. Blood group was determined 
by a 5’nuclease assay (Taqman; Applied Biosystems, Foster City, CA) using a standard PCR 
reaction mix (Eurogentec, Seraing, B) and an allele specific fluorescent probe equipped 
with a minor grove binding moiety (applied Biosystems, Foster City, CA).
statistical analysis
As estimates of relative risks, we calculated odds ratios (ORs) with 95% confidence 
intervals (CI95) using logistic regression. We determined associations between venous 
thrombosis risk and factor V Leiden (FVL), the prothrombin G20210A mutation (PT), 
ABO blood group, and a positive family history. All reported ORs were adjusted for age 
(continuous), sex (categorical), and study centre (Leiden and Haarlem versus Vermont, 
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categorical) using multivariable logistic regression. Additional to the individual effect, 
the combined effect of the risk factors was studied. Furthermore, analyses were strati-
fied for provoked and unprovoked thrombosis, and type of thrombosis (DVT only or PE 
with or without DVT).
Of all participants, 25 (6%) cases and 13 (3%) control subjects did not know whether 
one of their first degree family members had experienced a venous thrombotic event. In 
the overall analyses, these individuals were classified as having a negative family history, 
however, we performed a sensitivity analysis in which the risk of thrombosis associated 
with a positive family history was calculated after exclusion of these individuals. The 
risk of thrombosis associated with a positive family history of thrombosis was studied 
in more detail by calculating ORs for having any affected first-degree relative, having a 
first-degree relative affected before the age of 50 years, and for having multiple affected 
first-degree relatives. We calculated the positive predictive value of family history to 
identify FVL and PT. IBM SPSS Statistics 20.0 for Windows (SPSS Inc, Chicago, Ill) was used 
for data analysis.
results
In this study, 401 cases and 431 control subjects were included (Table 1). 166 Cases 
(41%) were diagnosed with an isolated DVT and 235 (59%) were diagnosed with PE with 
or without DVT. DNA analysis for factor V Leiden was available for 394 (98%) cases and 
426 (99%) control subjects, for prothrombin G20210A mutation for 394 (98%) cases and 
427 (99%) control subjects and for ABO blood group for 376 (94%) cases and 416 (97%) 
control subjects.
table 1. Baseline characteristics of control subjects and cases
Controls Cases
n 431 401
men, n (%) 209 (48.5) 166 (41.4)
Age, mean (range) 77.5 (70-96) 78.7 (70-101)
type Vt, n (%)
 Deep vein thrombosis (DVT)





factor V leiden, n (%) 18 (4.2) 34 (8.6)
Prothrombin G20210A mutation, n (%) 7 (1.6) 9 (2.3)
non-o blood group, n (%) 232 (55.8) 231 (61.4)
Positive family history for Vt, n (%) 54 (12.5) 97 (24.2)
Provoking factors, n (%) 67 (15.5) 170 (42.4)
N = number, VT = venous thrombosis
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Prothrombotic variants, Abo blood group and risk of venous thrombosis
Out of 394 cases, 34 (8.6%) cases carried the FVL mutation (32 heterozygotes and 2 
homozygotes). Of the control subjects, 18 (4.2%) were heterozygous for the FVL muta-
tion and none of the control subjects were homozygous. Carriers of the FVL mutation 
(heterozygous and homozygous carriers combined) had a 2-fold increased risk of a first 
thrombosis (Table 2, OR 2.2, CI95 1.2-3.9), compared with participants who did not carry 
the FVL mutation. The FVL mutation was present in 19 of 162 cases with DVT (11.7%) 
and 15 of 232 cases with PE with or without DVT (6.5%), leading to odds ratios of 3.0 for 
DVT (CI95: 1.5-6.0), and 1.5 for PE (CI95 0.7-3.1). The odds ratios for provoked thrombosis 
and unprovoked thrombosis in the presence of FVL were similar (OR 2.2, CI95 1.0-4.4 for 
provoked thrombosis and OR 2.0, CI95 1.0-4.0 for unprovoked thrombosis). Nine cases 
(2.3%) and seven control subjects (1.6%) were heterozygous carriers of the prothrombin 
G20210A mutation, and none were homozygous. This led to an OR for prothrombin 
G20210A of 1.4 (OR 1.4, CI95 0.5-3.9). In presence of the PT mutation, the odds ratio for 
unprovoked thrombosis was 1.8 (CI95 0.6-5.4) while no association was observed for 
provoked thrombosis (OR 1.0, CI95 0.3-4.0). 231 (61.4%) cases had blood group non-O 
and 232 control subjects (55.8%), resulting in an OR of 1.3 (CI95 1.0-1.8) for blood group 
non-O. Blood group non-O was not associated with the risk of provoked thrombosis 
(OR 1.0, CI95 0.7-1.5), whereas the risk of unprovoked thrombosis was 1.6-fold increased 
(CI95 1.1-2.3).
We studied the combined effect of ABO blood group and the presence of either the 
two variants (i.e., FVL or PT mutation), with wildtype carriers of the FVL and PT variants 
with blood group O as the reference category. Individuals carrying either prothrombotic 














Factor V Leiden - 408 153/207 1† 1† 1†




- 420 165/220 1† 1† 1†
+ 7 3/6 1.4 (0.5-3.9) 1.0 (0.3-4.0) 1.8 (0.6-5.4)
Blood group O 184 71/74 1† 1† 1†
Non-O 232 89/142 1.3 (1.0-1.8) 1.0 (0.7-1.5) 1.6 (1.1-2.3)
Family history VT - 377 127/177 1† 1† 1†
+ 54 43/54 2.1 (1.5-3.1) 2.3 (1.4-3.6) 2.0 (1.3-3.1)
*OR adjusted for age, sex, study center
†reference category
N = number, VT = venous thrombosis
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variant and blood group non-O had a 2.3-fold increased risk of venous thrombosis (CI95 
0.9-5.9) and wildtype carriers of FVL and PT with blood group non-O had a 1.3-fold 
increased risk of venous thrombosis (CI95 1.0-1.8). Those with both blood group non-
O and a prothrombotic variant had a similar risk as those with blood group O and a 
prothrombotic variant (Table 3).
family history and risk of venous thrombosis
Family history of thrombosis was positive for 97 cases (24.2%) and 54 control subjects 
(12.5%). Individuals with a positive family history of thrombosis had a more than two-
fold increased risk of venous thrombosis compared with individuals without a positive 
family history of thrombosis (OR 2.1, CI95 1.5-3.1). The association was similar when 
subjects who did not know their family history were excluded from the analysis (OR 2.2, 
CI95 1.5-3.2). The risk of both provoked and unprovoked thrombosis was increased in 
the presence of a positive family history, i.e., OR provoked thrombosis: 2.3 (CI95 1.4-3.6); 
OR unprovoked thrombosis: 2.0 (CI95 1.3-3.1). The risk of venous thrombosis was not 
increased when only family members who had thrombosis before the age of 50 years 
were considered positive (OR 0.8, CI95 0.5-1.4), taking individuals without a positive 
family history as a reference. The number of affected relatives was also not associated 
with the risk of thrombosis, having more than 1 positive family member versus only 
1 positive family member resulted in an OR of 0.8 (CI95 0.4-1.8). To assess whether a 
positive family history was mainly determined by the presence of the factor V Leiden 
or the prothrombin G20210A mutations, we studied the association between a family 
history of thrombosis and these prothrombotic variants. Out of 97 cases with a positive 
family history, 11 carried the FVL or PT variant. This results in a positive predictive value 
of positive family history for the FVL or PT variant of 11%.
In table 4 the associations of the combined risks of a positive family history of throm-
bosis and carrying the factor V Leiden or the prothrombin G20210A mutation are shown. 















− − 175 64/68 1† 1† 1†
+ − 8 7/6 2.3 (0.9-5.9) 2.5 (0.8-7.4) 2.1 (0.7-6.6)
− + 216 78/126 1.3 (1.0-1.8) 1.0 (0.7-1.5) 1.6 (1.1-2.3)
+ + 16 11/16 2.2 (1.1-4.3) 1.8 (0.8-4.1) 2.5 (1.2-5.4)
*OR adjusted for age, sex, study center
†reference category
N = number, FVL = Factor V Leiden, PT= Prothrombin G20210A mutation
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Individuals with a positive family history of venous thrombosis who also carried either a 
prothrombotic variant had a high risk of thrombosis (OR 7.6, CI95 1.6-35.7).
disCussion
In this population-based case-control study of 832 individuals aged 70 years and older, 
we show that factor V Leiden, the prothrombin G20210A mutation, and non-O blood 
group are risk factors for venous thrombosis in older individuals (≥70 years) as they are 
in younger individuals, increasing the risk of venous thrombosis 2.2-, 1.4-, and 1.3-fold 
respectively. Furthermore, a positive family history of thrombosis increased the risk of 
thrombosis 2.1-fold, without an effect of the number of affected family members and 
their age of onset. The highest risk of thrombosis was found in individuals who had both 
a positive family history and were carriers of one of the two prothrombotic variants.
The FVL and PT variants are well established risk factors in young and middle-aged 
individuals. The risk is four- to sevenfold increased for FVL carriers and two- to threefold 
increased for the PT variant. [3,16] Our results indicate that the FVL and PT variants 
remain associated with the risk of thrombosis in older age, as previous small subgroup 
analyses showed. [17]
The risk of thrombosis was highest in the presence of multiple genetic risk factors. 
These results illustrate the multicausal character of thrombosis, which is still present 
in older people. [1] Furthermore, the results are in line with studies explaining that the 
heterozygous mutations of the FVL and PT mutations are relatively weak risk factors 
for venous thrombosis, unless another genetic or acquired risk factor is present. [18] 
The finding of lower relative risks in older people than in middle-aged individuals may 
be partly explained by the higher absolute risk of venous thrombosis in older people 
which leads to smaller relative effects of individual risk factors in older people than in 
middle-aged individuals. Or, in other words, whereas the relative risks are smaller than in 















- - 350 112/155 1† 1† 1†
- + 51 38/48 2.1 (1.4-3.1) 2.2 (1.4-3.6) 2.0 (1.3-3.2)
+ - 23 13/17 1.7 (0.9-2.9) 1.7 (0.8-3.5) 1.6 (0.8-3.1)
+ + 2 5/6 7.6 (1.6-35.7) 7.1 (1.3-37.6) 7.7 (1.5-40.1)
*OR adjusted for age, sex, study center
†reference category
N = number, FVL = Factor V Leiden, PT= Prothrombin G20210A mutation
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the young, absolute risk differences for carriers versus non-carriers are substantial, given 
the high baseline risk in older people. Furthermore, our results may be due to attrition 
of susceptibles, indicating that susceptible individuals with FVL or PT are more likely to 
develop venous thrombosis earlier in life, resulting in lower relative risks at an older age.
Compared with blood group O, non-O individuals had a 1.3-fold increased risk of 
thrombosis. The increased risk can be partly explained by higher levels of FVIII and VWF 
in ABO blood group. [6,19,20] High FVIII levels are associated with a lowered respon-
siveness to activated protein C (APC). In carriers of factor V Leiden, this associated is 
strengthened, which explains the interaction between non-O blood group and factor V 
Leiden carriers. [6,21]
Family history and the two prothrombotic variants were poorly associated in this 
study, as was also indicated in previous studies. [7,10] The positive predictive value of 
family history as a test for genetic risk factors, i.e. FVL and PT, is low. This may indicate 
that unknown or unmeasured genetic risk factors are present in individuals with a posi-
tive family history. This hypothesis is supported by the finding of a 2.3-fold increased 
risk of thrombosis in persons with a positive family history and non-carriers of factor V 
Leiden and prothrombin G20210A variants.
The strength of our study is the specific focus on individuals aged 70 years and older. 
Home visits were performed in order to achieve a high participation rate (participation 
rate: cases 69%, control subjects 73%).
Our study has a number of limitations. Control subjects with a positive family history of 
venous thrombosis might be more willing to participate in a study of venous thrombosis 
than those who do not have a positive family history of thrombosis. However, this selec-
tion bias would only result in an underestimation of the true effect. Moreover, as in any 
case-control study, recall bias might have occurred when obtaining information on risk 
factors used for the classification into provoked and unprovoked thrombosis and family 
history. However, by using standardised interviews performed by trained personnel for 
both cases and control subjects, the risk of recall bias was minimised.
Our results may have clinical implications. A positive family history of venous throm-
bosis doubled the risk of venous thrombosis in older people. In clinical practice this 
information is easy to obtain, however it is not implemented in clinical decision rules of 
venous thrombosis. In older people these clinical decision rules show a high failure rate. 
[22] Potentially, obtaining information on family history of thrombosis in individuals 
aged 70 years or older could improve prediction of thrombosis in older people. [23]
In conclusion, factor V Leiden, prothrombin G20210A mutation, non-O blood group 
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AbstrACt
Venous thrombosis is common in older age, with an incidence of 0.5-1% per year in 
those aged ≥70 years. Stasis of blood flow is an important contributor to the devel-
opment of thrombosis and may be due to venous insufficiency in the legs. The risk of 
thrombosis associated with clinical features of venous insufficiency i.e., varicose veins, 
leg ulcer, and leg oedema obtained with a standardised interview was assessed in the 
AT-AGE study. The AT-AGE study is a case-control study in 70 years and older individuals 
(401 cases with a first-time venous thrombosis and 431 control subjects). We calculated 
odds ratios (ORs) and corresponding 95% confidence intervals (CI95) adjusted for age, 
sex, and study centre. Varicose veins were associated with a 1.6-fold (CI95 1.2-2.3) and 
a leg ulcer with a 3.3-fold increased risk of thrombosis (CI95 1.6-6.7), while the risk was 
3.0-fold (CI95 2.1-4.5) increased in the presence of leg oedema. The risk of thrombosis 
was highest when all three risk factors occurred simultaneously (OR: 10.5; CI95 1.3-86.1). 
In conclusion, clinical features of venous insufficiency, i.e., varicose veins, leg ulcer, and 
leg oedema are risk factors for venous thrombosis in older people.
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introduCtion
The incidence of venous thrombosis increases steeply with age, with an incidence of 
0.5-1% per year in people aged over 70 years. [1] More than 60% of all thrombotic events 
occur in this age group. [2]
Stasis of blood flow is, together with hypercoagulability and endothelial injury, an 
important contributor to the development of venous thrombosis according to Virchow’s 
triad. [3] Stasis can occur due to external pressure on the vein during, e.g., prolonged 
immobilisation or pregnancy, or due to venous insufficiency in the legs. Venous insuf-
ficiency comprises a spectrum of clinical features, including varicose veins, venous ulcer, 
and leg oedema. [4-6] Like venous thrombosis, the prevalence of venous insufficiency 
increases steeply with age. [7-9] There is limited information on the role of venous insuf-
ficiency in the development of venous thrombosis. In young and middle aged individu-
als, varicose veins strongly predispose to superficial thrombosis and are also associated 
with an increased risk of deep vein thrombosis. [10-12] The contribution of venous 
insufficiency to the incidence of venous thrombosis in the older population is unknown.
The aim of this study was to investigate whether clinical features of venous insuffi-
ciency defined as a history of varicose veins, leg ulcer, or leg oedema are risk factors for 
venous thrombosis in individuals aged 70 years and older. In addition, the contribution 
of these factors to the incidence of deep venous thrombosis was evaluated.
methods
Participants
The Age and Thrombosis Acquired and Genetic risk factors in the Elderly (AT-AGE) study 
is a two centre population-based case-control study. The study has been described in de-
tail previously. [13] In brief, between 2008 and 2011 all consecutive cases aged 70 years 
or older with an episode of deep venous thrombosis in the leg (DVT) or a pulmonary 
embolism (PE) were identified in defined geographical areas in Leiden, the Netherlands 
and Burlington, Vermont, US. In Leiden, cases were identified in two anticoagulation 
clinics (Leiden and Haarlem). In Vermont, cases were resided in a 45 km radius of Burl-
ington, and were diagnosed at the University of Vermont Medical Centre in Burlington, 
the only diagnostic centre in that area. Presence of DVT required positive compression 
ultrasonography or Doppler ultrasound. PE was considered definite in case of a posi-
tive spiral computed tomographic or high probability ventilation-perfusion lung scan. 
We defined venous thrombosis as DVT alone or PE with or without a proven DVT by 
ultrasound (PE±DVT). We invited the population-based control subjects randomly from 
primary care practices in the same geographic areas (five in Leiden and four in Vermont). 
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We defined the index date for the cases as the date of diagnosis of the thrombotic event. 
For control subjects the index date was the date of completing the interview at home. 
Individuals with active malignancy, defined as diagnosis of cancer, or chemotherapy or 
radiation therapy for cancer within six months before the index date, and those with 
severe psychiatric or cognitive disorders were excluded from participation, as were 
individuals who self-reported previous DVT or PE within the past 10 years.
Of 1187 identified cases, 689 (58%) were eligible. In Leiden, 398 (71%) of the 561 in-
vited cases and 321 (76%) of the 422 invited control subjects participated. In Burlington, 
128 cases were invited and 75 (59%) participated, while 140 (67%) of the 209 invited 
control subjects participated. Detailed information about the reasons for exclusion or 
not participating in the study can be found elsewhere. [13] All participants provided 
written informed consent. The study was approved by the Medical Ethical Committee of 
the Leiden University Medical Centre and by the Committee on Human Research of the 
University of Vermont.
data collection
During a home visit an extensive interview was performed by trained personnel. For 
the analyses on the aetiology of venous thrombosis we included the cases and control 
subjects without a history of venous thrombosis and who completed the interview at 
home (401 cases and 431 control subjects). For the cases, the median duration between 
the index date and the home visit was 5 weeks (range 1–44 weeks), 75% were visited 
within 7 weeks, and 90% were visited within 10 weeks.
In the interview information about the presence of well-known risk factors, such as 
recent hospitalisation, surgery, and fracture was obtained and a blood sample or buccal 
swab was collected. [13] The participants were asked about any prior history of varicose 
veins or leg ulcer or whether they had a history of leg oedema that lasted until at least 
the three months before the index date. Leg oedema was classified by participants as 
“daily oedema,” “intermittent oedema”, or “no oedema”. In the first version of the interview 
questionnaire of the control subjects the question of oedema was not incorporated yet. 
For this reason, for 24 control subjects we could not report this data.
We used self-assessed information on clinical features of venous insufficiency, a 
strategy that has been previously validated. [14] Additionally, among cases we obtained 
self-assessed information on the type and duration (in days) of possible thrombotic 
complaints prior to the diagnosis of the thrombotic event. The thrombotic event was de-
fined as provoked if in the three months before the thrombosis one of these conditions 
was present: hospitalisation, surgery, a fracture, plaster cast or splint use, a minor injury 
or immobilisation in the home situation. [13] Physical measurements were performed 
including weight (measured with a calibrated scale) and height. Body mass index (BMI) 
was calculated by dividing body weight (kg) by squared height (m²).
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statistical Analysis
To provide insight into the source population at the two study sites, we compared 
participant characteristics of control subjects, in Leiden and in Vermont. We studied the 
associations between potential confounders, i.e., sex and BMI and features of venous 
insufficiency in the complete control group.
The risk of venous thrombosis associated with the presence of history of varicose veins, 
leg ulcer, and leg oedema in the three months before the thrombosis was determined. 
We assessed a dose-response relation for oedema across groups of those with none, 
intermittent or daily oedema. The risk of thrombosis associated with the presence of 
one, two, or three of the symptoms of venous insufficiency was assessed.
Odds ratios (OR) and 95% confidence intervals (95CI) were calculated as an estimate 
of the relative risk of venous thrombosis. We used a multiple logistic regression model 
to calculate adjusted odds ratios. All reported ORs in the manuscript were adjusted for 
age (continuous), sex and study centre. Additionally, we adjusted for BMI (continuous), 
smoking status and the presence of the factor V Leiden or prothrombin 20210A mutation. 
Stratified analyses were performed by type of thrombosis (DVT and PE±DVT) and the 
presence of provoking factors, i.e. provoked and unprovoked first venous thrombosis.
We performed two analyses to address whether other causes of leg oedema than 
venous insufficiency explained our findings. Firstly, heart failure is associated with an 
increased risk of venous thrombosis and leg oedema can be present in individuals with 
heart failure. [15] To assess the risk of venous thrombosis associated with leg oedema 
as a symptom of venous insufficiency, we excluded participants with a self-reported his-
tory of heart failure. Secondly, to assess whether the presence of daily leg oedema might 
have been a (pre)clinical sign of the venous thrombosis (rather than due to venous 
insufficiency), we determined the risk of thrombosis associated with daily leg oedema in 
the individuals who reported a clinically asymptomatic event of venous thrombosis, e.g. 
individuals that did not reported any acute thrombotic complaints of the legs, or lungs 
before the diagnosis.
To assess the contribution of venous insufficiency to the incidence of venous throm-
bosis in this older population, we estimated the population attributable risk (PAR) of 
a history of varicose veins, leg ulcers, and daily leg oedema and the number of these 
symptoms combined. The PAR was calculated as pd (OR-1)/(OR), in which the pd is the 
prevalence of the risk factor among cases, and OR is the adjusted OR found in the study 




Characteristics of the control subjects of the two AT-AGE study centres are shown in 
table 1. In both centres, one third of the control subjects were 80 years or older. Median 
BMI was 25.9 kg/m2 (range 17.0-42.0 kg/m2) in Leiden, and 27.3 kg/m2 (19.0-49.7 kg/
m2) in Vermont. The prevalence of intermittent and daily leg oedema was similar at the 
two study centres, while the prevalence of varicose veins and leg ulcers was higher in 
Leiden than Vermont.
Symptoms of venous insufficiency were associated with sex and BMI. Women more 
often had varicose veins and leg oedema than men (varicose veins: women: 28.4%, men 
14.4%; oedema women: 17.1%, men 7.1%). Leg ulceration was rare and more common 
in men (3.3%) than women (1.8%). Individuals with obesity more often had leg oedema 
and leg ulceration than normal weight individuals but this association was less clear 
for varicose veins (BMI>30 compared with <25 kg/m²: oedema: 38.3% versus 16.1%, leg 
ulceration: 5.3% versus 1.3 %; varicose veins: 23.4% versus 20.6%). Symptoms of venous 
insufficiency were not associated with smoking status.
In table 2 the risk of venous thrombosis associated with symptoms of venous insuffi-
ciency are shown. Individuals with varicose veins had a 1.6-fold increased risk of venous 
thrombosis compared with individuals without varicose veins (OR 1.6; CI95 1.2-2.3). A 
history of a leg ulcer was associated with a 3-fold increased risk of thrombosis (OR 3.3; 
CI95 1.6-6.7). Leg oedema during the three months before thrombosis (daily and inter-
tabel 1. Characteristics of control subjects by study centre
Controls, n
leiden (nl) Vermont (us)
306 125
median Age (range) 76 (70-94) 76 (70-96)
70-75 years, n (%)
75-80 years, n (%)
80-85 years, n (%)









men, n (%) 147 (48.0) 62 (49.6)
median bmi (kg.m-2)(range)* 25.9 (17.0-42.0) 27.3 (19.0-49.7)
Varicose veins, n (%) 73 (23.9) 20 (16.0)











NL= the Netherlands, US= United States, n = number, BMI = Body Mass Index
*BMI 8 missings, †Leg oedema 24 missings
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mittent oedema combined) was associated with a 3.0 fold (CI95 2.1-4.5) increased risk of 
venous thrombosis compared with no oedema. There was a dose-response relationship 
of severity of oedema and the risk of venous thrombosis. Compared with individuals 
without oedema, individuals with intermittent oedema had a 1.6-fold increased risk 
of venous thrombosis (CI95 1.0 -2.5) while this risk was 3.1-fold increased for individu-
als with daily oedema (CI95 2.1-4.5). The associations between the clinical features of 
venous insufficiency and thrombosis remained present after adjustment for BMI and 
smoking (Table 2). Adjustment for the presence of the factor V Leiden and prothrombin 
20210A mutation showed similar risk estimates: varicose veins: OR 1.7 (CI95 1.3-2.4), 
leg ulcer: OR 3.4 (CI95 1.7-6.8), leg oedema: OR 3.1 (CI95 2.1-4.6). Excluding individuals 
with heart failure (20 cases and 19 controls) did not change the risk associated with 
leg oedema, i.e., compared with no oedema, the risk of venous thrombosis was 1.5-fold 
increased for intermittent oedema (OR 1.5; CI95 1.0-2.3) and 3.2-fold increased for daily 
oedema (OR 3.2; CI95 2.1-4.8). For 376 cases (93.8%), information on the presence or 
absence of thrombotic complaints prior to the diagnosis of venous thrombosis was 
available. Of the cases, 322 (85.6%) reported leg complaints specifically attributable to 
the subsequent diagnosis of venous thrombosis, whereas 54 (14.4%) did not. Among 
the latter, daily leg oedema was associated with a 2.6 fold (CI95 1.3-5.2) increased risk 
of venous thrombosis compared with no leg oedema. Of the cases, 219 (54.6%) had an 
unprovoked venous thrombotic event. Varicose veins were associated with a 1.3-fold 
(CI95 0.9-2.0) increased risk of an unprovoked venous thrombosis. For leg ulcer this risk 
was 3.2-fold increased (CI95 1.4-6.9) and for leg oedema (daily and intermittent oedema 
combined) 3.4-fold (CI95 2.1-5.3). For provoked venous thrombosis we found a 2.0-fold 
(CI95 1.4-2.9) increased risk for varicose veins, and a 3.4-fold increased risk (CI95 1.5-7.4)
for leg ulcer. Leg oedema was associated with a 2.8-fold (CI95 1.7-4.4) increased risk of 
provoked thrombosis.











Varicose Veins, n (%) 131 (32.7) 93 (21.6) 1.8 (1.3-2.4) 1.6 (1.2-2.3) 1.6 (1.2-2.3)
leg ulcer, n (%) 35 (8.7) 11 (2.6) 3.7 (1.8-7.3) 3.3 (1.6-6.7) 3.0 (1.5-6.2)
leg oedema, n (%)‡§
leg oedema‡§
 Never, n (%)
 Intermittent, n (%)





















n = number, OR = odds ratio, CI = confidence interval, ref= reference group.
*Adjusted for age (continuous), sex, and study centre.
†Further adjustment: BMI (body mass index)(continuous) and smoking status.
‡Leg oedema: no versus daily leg oedema. §Leg oedema: 29 missings.
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To assess the association of severity of venous insufficiency with risk of venous 
thrombosis, we determined the risk associated with number of venous insufficiency 
symptoms. The presence of one, two or three of the clinical features gradually increased 
the risk of thrombosis with the highest risk of venous thrombosis associated with the 
presence of all three clinical features compared with none of the features (OR: 10.5; CI95 
1.3-86.8) (Table 3). Of the cases, 166 (41%) were diagnosed with DVT only, and 235 (59%) 
with PE±DVT. The associations of venous insufficiency features with thrombosis risk 
were similar for both types of thrombosis except that the association of leg ulcer with 
DVT appeared stronger than the association with PE±DVT (Table 4).
The PAR of the three manifestations of venous insufficiency was 12.3% for varicose 
veins, 6.0% for a leg ulcer and 22.0% for the presence of leg oedema. The PAR of pres-
ence of two symptoms of venous insufficiency was 22.7%, and for presence of three 
symptoms, 4.6%.









no risk factor 149 (47.2) 249 (66.9) 1 (ref ) 1 (ref )
one risk factor, n (%) 167 (52.8) 123 (33.1) 2.3 (1.7-3.1) 2.2 (1.6-3.0)
two risk factors, n (%) 72 (32.6) 34 (12.0) 3.5 (2.2-5.6) 3.3 (2.1-5.3)
three risk factors, n (%) 8 (5.1) 1 (0.4) 13.4 (1.7-108.0) 10.5 (1.3-86.1)
n = number, OR = odds ratio, CI = confidence interval, ref= reference group.
*Adjusted for age (continuous), sex, and study centre.
table 4. Odds ratios of thrombosis with venous insufficiency stratified by type of thrombosis
n, dVt/total Vt (%) dVt or adjusted (Ci95)* Pe±dVt or adjusted (Ci95)*
Varicose veins 52/131 (39.7) 1.7 (1.1-2.5) 1.6 (1.1-2.3)
leg ulcer 18/35 (51.4) 4.3 (2.0-9.4) 2.4 (1.1-5.3)
leg oedema† intermittent 26/60 (43.3) 1.7 (1.0-3.0) 1.5 (0.9-2.5)
leg oedema† daily 42/111 (37.8) 2.8 (1.8-4.6) 3.2 (2.1-5.0)
N = number, DVT = deep vein thrombosis of the leg, PE= pulmonary embolism, OR = odds ratio, CI = con-
fidence interval.
*Adjusted for age (continuous), sex and study centre.
†Leg oedema: 29 missings.
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disCussion
In this population-based case-control study among individuals aged 70 and older, 
symptoms of venous insufficiency, i.e., a history of varicose veins, leg ulcer, and oedema 
increased the risk of venous thrombosis (both DVT and PE), with ORs ranging from 1.6 
to 3.0. The risk of venous thrombosis increased with severity of the venous insufficiency, 
defined as the number of clinical features. The risk was highest in individuals with all 
three clinical features combined (OR 10.5), although presence of all three features was 
uncommon. In agreement with the literature, venous insufficiency was common, both 
in the cases and control subjects, [8] leading to a high PAR of venous thrombosis associ-
ated with varicose veins and leg oedema. Adjustments for potential confounders did 
not influence the finding that clinical features of venous insufficiency are risk factors for 
thrombosis. Moreover, restricting the analysis to cases with unprovoked venous throm-
bosis demonstrated that the risks associated with symptoms of venous insufficiency are 
not explained by the presence of other major risk factors of thrombosis in the older 
population, such as recent hospitalisation and surgery. [13]
Some, but not all, studies have reported that varicose veins are associated with an 
increased risk of DVT and PE in the young and middle-aged. [12, 17-20] Heit et al. dem-
onstrated a 4-fold increased risk of venous thrombosis associated with varicose veins 
in middle-aged up to age 60 years, but in contrast to the current study, they observed 
no increased risk in those 70 years and older. [12] This difference in findings may be 
due to a difference in data collection. Heit et al. used medical record to assess chronic 
venous insufficiency, and we collected data on clinical features of venous insufficiency 
by an interview. Mild disorders, such as varicose veins, may be documented less often in 
medical records of older individuals, particularly when other co-morbidities are present, 
potentially resulting in underestimation of relative risks.
To our knowledge, presence of leg oedema due to chronic venous insufficiency has 
not been investigated as a risk factor for venous thrombosis in the older population. Leg 
oedema could be a pre-clinical sign of thrombosis; however, we showed that among 
individuals who did not report any thrombotic complaints prior to the diagnosis of 
venous thrombosis, leg oedema was still associated with a more than two-fold increased 
risk of thrombosis compared with no oedema. This indicates that our findings are not 
likely explained by leg oedema being a symptom of deep vein thrombosis. Heart failure 
as an underlying cause of leg oedema may explain the association between leg oedema 
and venous thrombosis. However, in our study excluding the individuals with heart 
failure did not change the results. We hypothesise several mechanisms by which venous 
insufficiency may increase the risk of venous thrombosis. Firstly, varicose veins, due 
to dysfunction of the venous valves, lead to low sheer stress in the veins and reduced 
blood flow, which subsequently lead to a pro thrombotic state. [21,22] It has been hy-
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pothesised that damage to the valves results in hypoxia especially in the valve pockets, 
which promotes thrombus formation at this location. [23] Secondly, inflammation may 
play an important role. Leg oedema as a result of long-term venous insufficiency could 
lead to mediator release and inflammation in the veins. [24,25] Leg ulceration is also as-
sociated with local inflammatory processes. [26] We hypothesise that this inflammatory 
state could initiate local thrombus formation within the leg veins. A leg ulcer is the most 
severe expression of venous insufficiency of the three clinical features that we assessed 
in this study. [27] In concordance with this, among the venous insufficiency features 
evaluated, the strongest association with thrombosis risk was found for leg ulcer. Finally, 
it has been suggested that venous insufficiency in the absence of a prior history of DVT 
may be due in part to prior undiagnosed DVT, which might increase the risk of future 
clinically apparent DVT. [28]
In the AT-AGE study we achieved high participation rates, which is challenging in 
older people. [29] As venous thrombosis and venous insufficiency are both associated 
with immobility, performing home visits to both cases and control subjects, minimised 
selection bias due to selection of only mobile older individuals. Moreover, by perform-
ing interviews we were able to determine risk factors that are not reported regularly 
in medical reports. Limitations of the current study require consideration. Recall bias 
may have affected our results, although we minimised this by performing standardised 
interviews, in both the cases and the control subjects. Referral bias could play a role in 
our results, e.g., if individuals with varicose veins are more likely to be referred for ultra 
sound of the legs, resulting in an overestimation of the risks. However, as we also found 
an increased risk for pulmonary embolism with clinical features of venous insufficiency, 
we do not expect a major influence. As the clinical features of venous insufficiency were 
all self-reported, over or under reporting of the clinical features cannot be ruled out. If 
misclassification is present, we would expect that the misclassification would be non-
differential in the cases and the control subjects. This may have led to an underestima-
tion of the risks. Ideally, clinical examination of the legs before the thrombotic event 
should have been performed. The AT-AGE study is a predominantly Caucasian study, 
thus we were not able to address racial differences in the associations.
In conclusion, clinical features of venous insufficiency were risk factors for venous 
thrombosis in this older population. This gives further insight into the aetiology of 
venous thrombosis in older people. Physicians may be more alert on thrombosis when 
one of the clinical features of venous insufficiency is present as these contribute to the 
burden of venous thrombosis in this older patient group.
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Venous thrombosis incidence increases with age. The role of age-specific risk factors in 
thrombosis etiology at older age, such as functional impairment, is unclear.
objective
Assess the thrombotic risk associated with functional impairment, defined as impaired 
activities of daily living (ADL), impaired mobility, sedentary lifestyle, and low handgrip 
strength.
methods
The AT-AGE study is a two-centre case-control study conducted in the Netherlands and 
the USA (2008-2011). Consecutive cases (n=401) aged 70 years and older with a first-
time deep venous thrombosis in the leg or pulmonary embolism and control subjects 
≥70 years (n=431) without a history of thrombosis were included. Exclusion criteria were 
active malignancy and severe cognitive disorders. Estimations of the risk of thrombosis 
associated with two or more impaired Katz ADL items, inability to walk outside for 15 
minutes, sedentary life style (>20 hours per day) and low handgrip strength (<15%) 
were performed. Odds ratios (ORs) adjusted for age, sex, and study centre with 95% 
confidence intervals (CI95) and population attributable risks (PAR) were calculated.
results
Impaired ADL was associated with a 2.9-fold (CI95 1.6-5.3) increased risk of venous 
thrombosis, impaired mobility with a 3-fold (OR 3.0 (CI95 1.9-4.7)), a sedentary lifestyle 
with a 4-fold (OR 4.0 (CI95 2.5-6.3)) and low handgrip strength with a 2.3-fold (CI95 1.5-
3.4) increased risk of thrombosis. The PARs for ADL disability, inability to walk outside 
for 15 minutes, sedentary lifestyle, and low hand grip strength were 8%, 13% 29%, and 
13%, respectively.
Conclusion
In those over 70 years of age, functional impairments are major risk factors for venous 
thrombosis. Findings may have important implications for awareness of venous throm-
bosis risk by providers caring for older people.
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introduCtion
The incidence of venous thrombosis increases steeply with age. [1] The oldest old have 
a 100-fold increased risk of venous thrombosis compared with young people, thus age 
is one of the most important risk factors. It is unclear why ageing leads to an increased 
incidence of thrombosis, and it is remarkable that few data are available on risk factors 
that are almost exclusively present in older individuals, i.e., age-specific risk factors. [2] 
With ageing a decline in physiological functioning occurs with an increased susceptibil-
ity to functional impairments. Functional impairment predisposes to adverse health out-
comes including death. [3-5] Functional impairment is associated with an inflammatory 
state, which promotes pro-coagulation [6], so functional impairment associated with 
ageing could result in an increased risk of venous thrombosis. Functional impairment is 
also associated with reduced mobility [3] An increased risk of thrombosis with mobility 
impairment would be expected based on the detrimental effects on muscular pump 
function and subsequent stasis of blood flow in the lower extremities. [6]
To study whether impaired functional status is an age-specific risk factor for venous 
thrombosis, we evaluated the associations between impaired functional status, ex-
pressed as disability of activities of daily living (ADL), impairment of mobility, sedentary 
lifestyle, and impaired hand grip muscle strength, and the occurrence of venous throm-
bosis in individuals aged 70 years and older.
methods
A detailed description of the Age and Thrombosis - Acquired and Genetic risk factors in 
the Elderly (AT-AGE) study has been published previously. [7] In brief, AT-AGE is a two-
centre population-based case-control study among individuals aged 70 years and older 
to determine risk factors for venous thrombosis in the older population. Individuals 
aged 70 years and older with a first occurrence of deep vein thrombosis of the leg (DVT) 
and/or pulmonary embolism (PE) were enrolled in the Leiden area (the Netherlands) 
and Burlington (Vermont, United States). Control subjects were randomly selected from 
several primary care practices in the same geographical area as the cases. For both the 
cases and the control subjects, exclusion criteria were the presence of an active malig-
nancy and psychiatric or cognitive disorders that hindered communication during the 
first contact. All participants provided written informed consent and gave permission to 
obtain information about their medical history. The study was approved by the Medical 
Ethical Committee of the Leiden University Medical Centre and by the Committee of 
Human Research of the University of Vermont. In Leiden, 504 cases were invited and 341 
(68%) participated. In Burlington, 115 cases were invited and 62 (54%) participated. Of 
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the 407 invited control subjects in Leiden, 306 (75%) participated, while in Burlington 
127 (65%) of the 196 invited control subjects participated. [7] The index date for the 
cases was defined as the date of diagnosis of the thrombotic event and for control sub-
jects, this was the date of completing the interview. At enrollment, a structured detailed 
interview took place at the participant’s home. The median duration between the index 
date and the home visit for the cases was 5 weeks (range 1–44 weeks), 75% were visited 
within 7 weeks, and 90% were visited within 10 weeks.
We used four instruments during the home visit to ascertain functional status prior to 
the index date. For ADLs we used the Katz Index [8] which includes questions on whether 
the participant was independent in six daily activities by yes/no answers: bathing, dress-
ing, toilet use, transferring in and out of bed, eating, and presence of urinary or bowel 
incontinence. The range of the impairment score can be 0 of 6 (no ADL impairment) to 
6 of 6 (fully ADL impaired). We used two items of the Barthel index to assess impairment 
of mobility; ability to walk outside for 15 minutes and ability to climb stairs. [9] We also 
estimated sedentary lifestyle by querying participants about the percentage of time 
spent sleeping and sitting per day during the two weeks before the index date. [10,11] 
Measurement of hand grip strength was performed twice in the dominant hand using 
a Jamar dynamometer, with the highest result used. [12] Weight was measured with a 
calibrated scale and height was measured. Body-mass index was calculated in kg per 
m². We also obtained information about the presence of other diseases such as a history 
of myocardial infarction and chronic obstructive pulmonary disease, and about other 
risk factors for venous thrombosis including recent hospitalisation, surgery, fracture, 
plaster cast or splint use, and minor injury or immobilisation. [7] A provoked event was 
defined when one of the following conditions was present in the three months before 
the thrombotic event: recent hospitalisation, surgery, fracture, plaster cast or splint use, 
minor injury or immobilisation in the home situation.
Analyses
We included cases and control subjects who completed the interview (401 of the 403 
cases and 431 of the 433 control subjects). Characteristics of the control subjects were 
tabulated by study centre. We estimated the risk of venous thrombosis associated with 
the following expressions of the Katz ADL instrument: ‘yes’ versus ‘no’ to each of the 
6 items of the Katz score, ADL disability present, defined as ≥ two impaired Katz ADL 
items compared to no impairment and for ≥ 3 impairments versus none. Impairment 
of mobility was present if an individual was not able to walk outside for 15 minutes. [9] 
Impairment of mobility was also separately analysed measured by the ability to climb 
stairs. A sedentary lifestyle was analysed by comparing individuals who spent 14 hours 
or less sleeping or sitting (20th percentile in the control subjects) with individuals who 
spent 20 hours or more sleeping or sitting (80th percentile in the control subjects). We 
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also considered tertiles of the hours of sedentary time, with the lowest tertile as the 
reference category. As handgrip strength is sex dependent, we assessed risk by compar-
ing participants below versus above the sex-specific 15th percentile hand grip strength 
in the control group (<26 kg in men, and <16 kg in women). [13,14] We also assessed 
handgrip strength in sex specific tertiles based on the distribution in control subjects.
For all analyses, multivariable logistic regression models were used to estimate the odds 
ratios (ORs) and their 95% confidence intervals (CI95s) as estimates of the relative risk. All 
odds ratios were adjusted for the pre- defined potential confounders, age (continuous), 
sex and study centre. As weight loss is seen as an important marker of functional status, 
[3] further adjustments were made for BMI in three categories, <25kg/m2, 25-30 kg/m2 
and >30kg/m2). Also adjustments were performed for the presence of co-morbidities 
(a history of myocardial infarction, transient ischemic attack, stroke, heart failure, or 
chronic obstructive pulmonary disease). To assess whether the association of functional 
impairment and thrombosis varied within the three BMI groups, we performed stratified 
analyses for all four functional impairments within the three BMI groups. The risk as-
sociated with an impaired functional state was calculated for provoked and unprovoked 
venous thrombosis and DVT and PE separately. To investigate whether an accumulation 
of functional impairments would influence the risk of thrombosis, we calculated the risk 
of thrombosis associated with the number of impairments present (1-4).
To obtain insight into the contribution of impaired functional state to the incidence 
of venous thrombosis in the older population we estimated the population attributable 
risk (PAR) for each of the four functional state entities. The PAR was calculated by pd 
(OR-1)/(OR). In which pd is the prevalence of the risk factor among cases, and OR is the 
adjusted OR. All statistical analyses were performed using SPSS 20 for Windows (SPSS 
Inc, Chicago, Ill).
results
Median age was similar for control subjects in the Netherlands (76 years (range 70-94) 
and the United States (76 years, range 70-96). Distributions of sex and BMI (kg.m−2) were 
also similar between the two centres (Table 1). The prevalence of impaired functional 
status by each of the four measures was low among controls, with sedentary lifestyle 
being the most prevalent. Since no major differences in other variables were observed, 
we combined data from the two centres for all analyses.
The separate Katz ADL items were each associated with venous thrombosis. The 
adjusted ORs for impairment of bathing, getting dressed, toilet use, eating, transferring 
in and out of bed (or chair) and the presence of urinary or bowel incontinence were 
respectively: 2.0 (CI95 1.2-3.2), 3.9 (CI95 1.9-8.2), 16.1 (CI95 2.1-124.9), 5.7 (CI95 0.6-51.1) 
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13.9 (CI95 1.8-109.5), and 1.5 (CI95 1.0-2.3). In table 2, the associations of four functional 
impairment entities with venous thrombosis are presented. The risk of thrombosis in-
creased 3-fold (OR 2.9; CI95 1.6-5.3) when two or more impairments were present on 
the ADL score compared with no impairments. Impairment of mobility was associated 
with a 3-fold (CI95 1.9-4.7) increased risk. The risk of thrombosis was up to 4-fold higher 
in individuals with a sedentary lifestyle defined as ≥20 hours of sitting/sleeping than in 
the group of ≤14 hours (OR 4.0; CI95 2.5-6.3). A gradually increasing risk of thrombosis 
was also found across tertiles of hours of sedentary time. Low handgrip strength was 
associated with a 2.3-fold (CI95 1.5-3.4) increased risk of thrombosis.
Functional impairment entities were associated with BMI in the control subjects. Im-
pairment on the ADL score was lowest in the middle BMI group (1.7%) and 3.9% in the 
low, 4.3% in the high BMI group. Impairment of mobility was highest (10.6%) in the high 
BMI group. Impairment of mobility was present in 4.5% in the low BMI group, and 6.9% 
in the middle BMI group. A sedentary lifestyle was present in 17.2% in the low BMI group, 
17.5% in the middle BMI group, and 29.0% in the high BMI group. There was no associa-
tion between BMI and low hand grip strength (low: 13.5%, middle: 10.9%, high: 11.6%).
Additional adjustment for BMI did not alter the associations of any of the four func-
tional impairment measures with thrombosis risk. Stratified analyses by BMI group for all 
four functional impairment entities showed that functional impairment was associated 
with thrombosis in each group. In the lowest BMI group, impairment of the ADL score 
was associated with a 1.9 fold (CI95 0.6-5.4) increased risk, in the middle BMI group and 
table 1. Characteristics of control subjects by center
Controls nl Controls us
number of Participants 306 125
male sex (%) 147 (48) 62 (50)













median bmi* (range) 26 (17-42) 27 (19-49)













inability to walk outside 15 min (%) 23 (8) 9 (7)
sedentary lifestyle (>20 h/24 h) (%) 138 (12) 18 (14)
impaired hand grip strength (%) 25 (8) 19 (15)
NL= Netherlands, US= United States
* BMI = Body Mass Index kg.m-2;
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the high BMI group, a risk of 5.9 (CI95 1.7-20.8) and 2.4 (CI95 0.7-8.1) was found. Cor-
responding ORs for impairment of mobility for the three BMI groups were 3.7 (CI95 1.5-
9.1), 3.1 (CI95 1.5-6.5) and 2.2 (CI95 0.9-5.4). For a sedentary lifestyle these ORs were 3.7 
(CI95 2.0-6.6), 3.6 (CI95 2.1-6.2) and 2.8 (CI95 0.9-3.3). A low handgrip strength increased 
the risk of thrombosis in the low BMI group 2.2 fold (CI95 1.0-4.5), 1.6 fold (CI95 0.8-3.3) 
in the middle group, and 2.9 (CI95 1.2-7.0) in the high BMI group.
Associations between the impairments and thrombosis risk were similarly present 
after adjustments for the presence of co-morbidities. (table 2) Functional impairment 
was associated with an increased risk of both DVT and PE. Presence of two or more im-












0 vs ≥ 2 disabilities 50 (14.6) 16 (4.1) 4.0 (2.2-7.1) 2.9 (1.6-5.3) 2.9 (1.5-5.6) 2.7 (1.5-5.2)
Number of disabilities
0 (%) 292 (84.1) 370 (89.4) 1 (ref ) 1 (ref ) 1 (ref ) 1 (ref )
1 (%) 55 (15.9) 44 (10.6) 1.6 (1.0-2.4) 1.3 (0.8-2.0) 1.3 (0.8-2.1) 1.2 (0.7-1.9)
2 (%) 23 (7.3) 10 (2.6) 2.9 (1.4-6.2) 2.1 (1.0-4.7) 2.6 (1.1-6.1) 1.7 (0.7-3.9)
≥ 3 (%) 27 (8.5 ) 6 (1.6) 5.7 (2.3-14.0) 3.9 (1.5-9.8) 3.1(1.1-8.7) 3.9 (1.5-10.3)
impairment of mobility
Walk outside, not able (%) 78 (19.5) 32 (7.4) 3.0 (2.0-4.7) 3.0 (1.9-4.7) 2.9 (1.8-4.7) 2.8 (1.7-4.6)
Climbing stairs, not able (%) 72 (18.0) 29 (6.7) 3.0 (1.9-4.8) 2.4 (1.5-3.9) 2.2 (1.3-3.7) 2.1 (1.3-3.5)
sedentary lifestyle
20th percentile (≤14 h) 42 (10.6) 92 (23.2) 1 (ref ) 1 (ref ) 1 (ref ) 1 (ref )
80th percentile (≥20h) 173 (43.6) 90 (22.7) 4.2 (2.7-6.6) 4.0 (2.5-6.3) 4.4 (2.7-7.2) 4.0 (2.4-6.8)
Tertiles
< 16 h 68 (17.4) 133 (31.5) 1 (ref ) 1 (ref ) 1 (ref ) 1 (ref )
16-18 h 115 (29.5) 156 (37.0) 1.4 (1.0-2.1) 1.4 (0.9-2.0) 1.3 (0.9-2.0) 1.3 (0.9-2.0)
>18 h 207 (53.1) 133 (31.5) 3.0 (2.1-4.4) 2.8 (1.9-4.1) 2.8 (1.9-4.1) 2.7 (1.8-4.0)
low hand grip strength
<15% 92 (23.2) 50 (11.6) 2.3 (1.6-3.3) 2.3 (1.5-3.4) 2.1 (1.4-3.2) 1.7 (1.1-2.6)























* adj for age, sex and study center **adj for age, sex, study center and BMI ***adj for age, sex, study center 
and co-morbidities
˦  ADL missing cases 4; missing control subjects 1; Impairment of mobility: missing cases 1 missing control 
subjects 1; Sedentary lifestyle: missing cases: 11 missing control subjects 9; Low handgrip strength: missing 
cases: 4 missing control subjects: 1
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pairments on the ADL score was associated with a 3.8 fold (CI95 1.9-7.6), increased risk 
of DVT and of 2.3 fold (CI95 1.1-4.5) increased risk of PE. Impairment of mobility had an 
odds ratio for DVT of 3.2 (CI95 1.9-5.4), and of PE of 2.6 (CI95 1.6-4.4). Sedentary lifestyle 
increased the risk for both DVT and PE (OR DVT 2.6; CI95 1.8-3.9, OR PE 3.1; CI95 2.2-4.5). 
Unlike the other measures, low handgrip strength was mainly associated with DVT; OR 
3.1 (CI95 1.8-5.3) for DVT and 1.7 (CI95 1.1-2.8) for PE. Of the 401 cases, 182 (45.4%) had 
a provoked venous thrombotic event. In general, the functional measures were more 
strongly associated with provoked events. For unprovoked thrombosis, two or more 
impairments on the ADL score was associated with a 1.8 fold (CI95 0.9-3.7) increased 
risk, impaired mobility was associated with an odds ratio of 2.4 (CI95 1.4-4.1), sedentary 
life style had an odds ratio of 1.7 (CI95 1.1-2.4), and low handgrip strength had an odds 
ratio of 1.8 (CI95 1.1-2.9). For the provoked events the odds ratio of thrombosis was 4.9 
(CI95 2.3-8.7) when two or more impairments on the ADL score were present, while this 
was 3.6 (CI95 2.1-5.9) for impaired mobility, 5.4 (CI95 3.6-8.1) for sedentary lifestyle and 
2.8 (CI95 1.7-4.7) for impaired handgrip strength.
Table 3 shows that the number of functional impairment entities was positively 
associated with risk of venous thrombosis. The prevalence of at least one functional 
impairment was 56.5% in the cases (221 of 391) and 28.7% the control subjects (121 of 
422). Compared with those with no impairments, the OR of thrombosis increased from 
3.0 (CI95 2.1-4.3) when one impairment was present, up to 25.1 (CI95 3.2-195.0) when 
four impairments were present.
Population attributable risk estimates the proportion of a disease attributable to a risk 
factor under the assumption of causality. The PARs for sedentary lifestyle, ADL disability, 
inability to walk outside for 15 minutes and low hand grip strength were 29%, 8%, 13% 
and 13%, respectively.












n= 0 170 (43.5) 301 (71.3) 1 (ref ) 1 (ref ) 1 (ref ) 1 (ref )
n= 1 121 (30.9) 72 (17.1) 3.0 (2.1-4.2) 3.0 (2.1-4.3) 3.2 (2.2-4.6) 2.9 (2.0-4.3)
n= 2 50 (12.8) 34 (8.1) 2.6 (1.6-4.2) 2.8 (1.7-4.5) 2.8 (1.7-4.7) 2.4 (1.4-4.0)
n= 3 34 (8.7) 14 (3.3) 4.3 (2.2-8.2) 4.4 (2.2-8.6) 4.1 (2.0-8.3) 3.0 (1.5-6.3)
n= 4 16 (4.1) 1 (0.2) 28.3 (3.7-215.5) 25.1 (3.2-195.0) 18.8 (2.4-148.1) 22.9 (2.8-186.1)
*adj for age, sex and study center
**adj for age, sex, study center and BMI
***adj for age, sex, study center and co-morbidities
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disCussion
In a two-centre population-based study of people over age 70, comprising 401 patients 
with thrombosis and 431 control subjects, we showed that functional impairment 
defined as an impaired ADL, impaired mobility, sedentary life style, and low handgrip 
strength were associated with an increased risk of venous thrombosis. These four mani-
festations of functional impairment each were associated with a 2- to 4-fold increased 
risk of thrombosis. Further, an increasing number of functional impairments was also 
associated with risk of thrombosis. The overall relative contribution of each functional 
impairment entity to the thrombotic risk, based on the PAR, varied from 8% to 29%. 
Furthermore, all functional impairment entities were also associated with unprovoked 
thrombosis, which suggests that the associations were not explained by the provoking 
factors for venous thrombosis. The associations of functional impairment with venous 
thrombosis were also present in the provoked thrombosis group, indicating that when 
other major risk factors are present in this older age group, functional impairment is also 
important.
Our findings are in line with previous reports that showed that functional impairment 
is associated with the risk of thrombosis. A cross-sectional analysis of older in-hospital 
patients illustrated that a decreased Katz ADL score was associated with 2-fold increased 
risk of asymptomatic thrombosis. [15] Furthermore, Folsom et al reported a 1.5- to 2-fold 
increased risk of future thrombosis with frailty, also a measure of functional status, in 
those 65 years and older. [16] Having a sedentary lifestyle or transient immobility have 
been previously reported as risk factors in both young and older populations. [7,17,18] 
In this study, the number of functional impairment markers was positively associated 
with the risk of venous thrombosis, indicating that impairment on several aspects, which 
likely reflects the severity, influences the risk of thrombosis.
Various causal mechanisms regarding the association of impaired functional status 
and venous thrombosis can be hypothesised. [16,19] Biological age is related with the 
functional status of an individual. [20] Age-related alterations of the venous vessel wall 
are postulated to provoke thrombus formation. [21,22] Low hand grip strength reflects 
loss of overall muscle mass and strength. A decline of leg muscle strength, and specifi-
cally calf muscles could result into stasis of the blood flow in the legs, and subsequently 
venous hypertension could induce a pro-thrombotic environment. [6] Furthermore, 
functional impairment with ageing is associated with inflammation and procoagula-
tion. [23,24] Thrombosis might occur more easily in older, impaired individuals due to 
deregulation of the blood coagulation system by increased inflammation and higher 
levels of D-dimer, factor VIII and von Willebrand factor [25], all of which are related to risk 
of venous thrombosis. [16,26]
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Strengths and limitations of this study require discussion. We performed home-visits, 
thereby allowing functionally impaired individuals to participate. This resulted in a high 
participation rate and minimised selection bias. [7] However, we cannot completely 
rule out that participation was related to the presence of functional impairment which 
would, if different in cases and controls, lead to biased estimates. If at all present, this 
would most likely have affected controls, with those with impairments participating less 
readily than those with. If this bias was present, the reported risks are an overestima-
tion. Recall bias may have been present for the self-reported measures, but not for the 
handgrip assessment. Handgrip strength could have been influenced by conditions 
associated with the venous thrombosis event, such as recent hospitalisation or surgery, 
but presence of associations in both unprovoked and provoked thrombosis suggests a 
minimal impact on interpretation of results. Despite the use of standardised question-
naires for both the cases and control subjects, we cannot rule out differential recall of 
functional status by case control status.
Functional impairment may be the result of disorders affecting the risk of thrombosis, 
leading to confounding. However, the risk of thrombosis remained clearly elevated also 
after adjustment for several diseases, such as myocardial infarction and pulmonary 
disorders. BMI was not a confounder in the association of functional impairment and 
venous thrombosis, although weight loss is seen as an important marker of functional 
status [3], and higher BMI is a risk factor of thrombosis in the middle aged population.
In conclusion, functional impairment is a risk factor for venous thrombosis in older 
people and the contribution of functional impairment to the overall incidence of ve-
nous thrombosis is high. The risk of thrombosis is increased in older individuals with 
functional impairments, also when other major risk factors are present. Moreover, accu-
mulation of multiple functional impairments signified substantial risk. Our findings have 
important implications for awareness of venous thrombosis risk by providers caring for 
older people.
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introduCtion
At advanced age, individuals are increasingly prone to develop diseases and multi 
morbidity is more frequently present. [1] Since life expectancy in developed countries 
is increasing, [2] research into causes and prevention of disease in the elderly is neces-
sary. Nevertheless, older people are underrepresented in research studies; Bugeja et 
al reported that one third of research articles in the BMJ, Gut, the Lancet, and Thorax 
published between June 1996 and June 1997, excluded older adults without justifica-
tion. [3] McMurdo et al repeated this analysis in 2005, and found that nearly 15% of 
articles still excluded older adults and that fewer than 5% of published articles focused 
specifically on older adults. [4] Several explanations for the scarcity of studies among 
older people may be postulated. [5-7] First, researchers may anticipate barriers to par-
ticipation such as mobility problems to reach their study centre. Second, impairments 
(e.g., visual and cognitive) of older people may make it difficult to participate. [8-10] 
Third, co-morbidities and competing risks among older people may play a role in influ-
encing study outcomes. Because of the lack of inclusion of older persons in key trials, 
external validation of findings from studies of younger persons to an older population 
may be questioned. [4,11,12] Furthermore, research studies that are conducted among 
older people often include the most vital individuals, i.e., without co-morbidities, recent 
surgery, or hospitalisation, which can make the generalizability of the study results 
questionable. Therefore, there is a need for research studies among the older people.
The incidence of venous thrombosis increases steeply with age and ~60% of all venous 
thrombosis events occur in those aged 70 years and older. [13] However, vast majority 
of studies into etiology, treatment and prevention of venous thrombosis are restricted 
to younger people. [14] Here we report on factors that affecting the participation of 
older patients in a population-based case-control studies on the etiology of venous 
thrombosis among older people (70-80 years). We compared the participation in older 
patients in the Multiple Environmental and Genetic risk factors for venous thrombosis 
(MEGA) and the Age and Thrombosis, Acquired and Genetic risk factors in the Elderly 
(AT-AGE) study. [15]
methods
The designs of the MEGA and the AT-AGE study have been described in detail previously. 
[15,16]. Both studies are population-based case-control studies designed to investigate 
acquired and genetic risk factors for venous thrombosis. From March 1999 onwards, In 
the MEGA study, all consecutive patients aged 18-80 years old with a first episode of 
venous thrombosis (deep venous thrombosis of the leg (DVT), the arm, or a pulmonary 
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embolism (PE)) were identified via the anticoagulation clinics in the Netherlands (6 clin-
ics: Amersfoort, Amsterdam, Den Haag, Leiden, Rotterdam, Utrecht). From March 2001 
until the end of the study in 2004, patients in age 70-80 years were no longer invited due 
to low agreement rates to participate. In the AT-AGE study, consecutive patients aged 
70 and older with a first DVT of the leg or PE between 2008 and 2011, were identified 
via the anticoagulation clinics in Leiden and Haarlem, the Netherlands and the Vascular 
Laboratory and the Radiology department of the University of Vermont Medical Centre, 
Burlington, Vermont, USA. In both the MEGA study and the AT-AGE study, patients with 
severe psychiatric problems or an inability to speak Dutch or English were excluded. In 
the AT-AGE study, patients with an active malignancy were also excluded.
For this manuscript we analysed the patients age 70-80 years included in the MEGA 
study and the AT-AGE study in the Netherlands. Patients were invited in a similar way in 
both studies, i.e., by means of a personalised invitation letter sent by the anticoagulation 
clinic followed by telephone contact by a dedicated data manager or trial nurse from 
the study centre. To allow comparisons in the MEGA and the AT-AGE study, MEGA study 
participants with active malignancy were excluded from this analysis.
Subsequent data collection differed for the two studies. In the MEGA study a detailed 
questionnaire on acquired risk factors for venous thrombosis was sent by mail to all 
patients. Patients who were unable or did not want to fill in the mailed questionnaire 
were approached by telephone and a short questionnaire was completed during the 
telephone interview. Blood samples were obtained approximately three months after 
discontinuation of anticoagulation treatment. If treatment duration was longer than one 
year, blood was sampled during treatment. For this blood draw all patients were invited 
to come to the anticoagulation clinic in their region. In the AT-AGE study all participants 
were visited at home twice. During the first home visit an interview was conducted by 
a trained research assistant and a detailed questionnaire on acquired risk factors for 
venous thrombosis was completed. During this home visit, a blood sample was drawn 
(to obtain DNA and non-vitamin K dependent coagulation factors). One year after the 
venous thrombosis (when most patients had discontinued anticoagulation therapy), a 
second home visit was conducted and, another blood sample obtained.
Analyses
For this study we calculated the participation rate for filling in a questionnaire (question-
naire participation rate) and for both filling in a questionnaire and donating a blood 
sample (overall participation rate). In the MEGA study the questionnaire participation 
rate was determined as the percentage of patients for whom there was a returned 
mailed questionnaire or for whom a short telephone administered questionnaire was 
completed. In the AT-AGE study, this was the percentage of patients for whom a first 
home visit was conducted, during which the study interview was completed. The overall 
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participation rate was calculated as the percentage of patients that finished the full re-
search study including filling in the questionnaire, and participating for blood sampling 
(for the AT-AGE study the second blood sample). To investigate whether the participa-
tion rate differed with age, we stratified the analyses by age groups 70-75 and 75-80 
years old. We also assessed the characteristics of the participating patients in the two 
studies, such as sex, BMI, and the presence of recent surgery.
results
The participation rate in the two studies is shown in figure 1. In the MEGA study, 446 
patients and in the AT-AGE study, 309 patients aged 70-80 years old were eligible to 
participate. In the MEGA study, 251 patients provided information on the questionnaire 
(56%) as compared with 224 patients in AT-AGE (72%). In the MEGA study the median 
time between the venous thrombotic event and the blood draw was 10 months (range 
3-25 months) and in the AT-AGE study this was 12 months (range 11-16 months). Of 
the patients 22 (8.8%) patients died in the MEGA study before the blood draw was 
performed compared with 11 patients (4.9%) in the AT-AGE study. In the MEGA study, 
a blood sample was provided by 53% of the patients (122 of 229 patients). In the AT-
AGE study this was 89% of the patients (189 of 213 patients). The overall participation 
(questionnaire participation plus blood draw)) was 27% (122/446) in the MEGA study 
and 61% in the AT-AGE study (189/309) (figure 1). Age-stratification demonstrated that 
the questionnaire participation rate was similar across the 5-year age-groups within the 
studies. (MEGA study 70-75 years: 56% (125/223) of which 51% men, 76-80 years: 57% 
(126/223) of which 52% men. In the AT-AGE study: 70-75 years: 74% (131/178), 76-80 
years: 71% (93/131). In the AT-AGE study 48% were men in the 70-75 years old group, 
and 40% in the 75-80 years old group.




(70-80 years) n (%)
Questionnaire participation
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DVT without PE, N (%)















N = number, DVT= deep venous thrombosis, BMI = Body Mass Index
MEGA: Multiple Environmental and Genetic risk factors for venous thrombosis
AT-AGE: Age and Thrombosis, Acquired and Genetic risk factors in the Elderly
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Characteristics of the participating patients in both studies are shown in Table 1. Pa-
tients included in the MEGA study were diagnosed more frequently with DVT only (59%) 
than patients in the AT-AGE study (39%). Hospitalisation and surgery three months prior 
to the thrombosis were more frequently present in the AT-AGE study than the MEGA 
study.
disCussion
In this study we show that participation rate of older patients in research is substantially 
increased (from 27% up to 61%) when home visits were used. Questionnaire participa-
tion via a structured interview during a home visit is superior to asking participants to 
complete a mailed questionnaire (72% versus 56% completion). Participation did not 
differ among those aged 70-75 compared to 75-80.
Reasons for higher participation via an in-home visit in old patients with thrombosis 
are likely related to mobility and social aspects, i.e., already having frequent hospital 
trips, reluctance to ask assistance of caregivers to participate in research, and a lack 
of personal contact with investigators for a mailed questionnaire. Visual or cognitive 
impairment are also more likely to deter participation in a questionnaire as compared 
to a home visit as participants may gain confidence when a research co-worker is 
assisting them to answer the questions. Davies et al. previously reported on the role 















figure 1. Participation rates in the MEGA and the AT-AGE study
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minimising the participant reluctance to participate in the New Castle 85+ study. [9] 
Moreover, it was previously recognised that the personal contact of a researcher during 
a home visit encourages older adults to be more dedicated to the research study, and 
thus to participate for a longer period. [17] Comparing the percentages of older patients 
with hospitalisation and surgery, we found higher prevalences in AT-AGE than in the 
MEGA study. This indicates that home visits increased participation rates also in the 
most vulnerable group. Unfortunately, we do not have reliable data on characteristics of 
the non-responders and the reasons why patients were not able or willing to participate. 
We cannot rule out that other study differences apart from the ones described here may 
explain a difference in the participation rate, e.g., in the AT-AGE study it was emphasised 
to the patients that this study was specifically focused on the older adults and this might 
have increased willingness to participate.
In conclusion, as the MEGA and the AT-AGE study were both performed in the same 
region (the Netherlands), study the same disease (venous thrombosis), and were per-
formed by the same investigators, we had the opportunity to compare the participation 
rates among older patients when using different approaches for inclusion. Home visits 
were an effective approach to increase the participation rate in this age group.
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introduCtion
Coagulation factor levels are commonly measured in research studies evaluating etiol-
ogy of diseases, in particular vascular diseases. Levels in the upper 10 percent (>P90) 
of the population distribution of procoagulant factors prothrombin, FVIII, FIX, FXI, and 
low levels of anticoagulation proteins are associated with an increased risk of venous 
thrombosis. [1-5] Many pre-analytical variables may affect the accuracy of these assays, 
including the duration of time from venipuncture to specimen processing and storage 
environment. [6,7] Clinic-based research settings are able to minimise the time from 
venipuncture to blood processing. However, immediate processing of blood samples 
is not feasible with some study designs, e.g., when samples are drawn in participant 
homes. In these settings, optimal sample handling should minimise pre-analytical fac-
tors that could impact coagulation factor level measurements.
Factor VII, factor VIII, and von Willebrand factors levels may be affected by a cold 
environment prior to centrifugation. [8-10] Pre-centrifugation storage temperature and 
time exposed to cold temperature prior to centrifugation did not appear to influence 
measured levels of factors prothrombin, V, VII, IX, XI and XII in the study of Favaloro. [8] 
Recommendations regarding the optimal temperature for storage prior to centrifugation 
of whole blood for performing coagulation factor assays are given in the fifth edition of 
the guidelines of the Clinical and Laboratory Standards Institute. [11] Cold storage prior 
to centrifugation of samples for factor VIII and von Willebrand factor is not advised in 
this guideline; however, no strict advice is given regarding the optimal sample handling 
conditions for other coagulation factors. This is due to the limited available evidence. 
The aim of this study was to assess the effect of differences in the time-interval between 
venipuncture and processing of blood on the levels of fibrinogen, prothrombin, factors 
VIII, IX, XI and antithrombin. Furthermore, the effect of storage of blood samples at dif-
ferent temperatures prior to centrifugation was assessed.
methods
A blood sample was obtained from 10 healthy volunteers; 4 males and 6 females with 
a mean age of 28 years (range 24–41 years). Venous blood was collected from the an-
tecubital vein into three tubes of 3.8% sodium citrate (Starstedt®). Venous access was 
achieved at first attempt in all participants and a tourniquet was placed for a maximum 
of 25 seconds. All volunteers gave informed consent and the study was approved by the 
Medical Ethical Committee of the Leiden University Medical Centre in the Netherlands. 
The three citrate tubes were processed separately. Tube A, the reference sample, was 
processed directly after blood sampling. The sample was centrifuged at 18°C for 10 min 
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at 2500g and the plasma was immediately stored at -80°C. Tube B was stored for 2.5 
hours at room temperature (~21˚C) while tube C was put on ice for 2.5 hours immedi-
ately after the venipuncture (~4˚C). After 2.5 hours both tube B and C were processed 
and stored similarly as tube A.
Analyses of the coagulation factor levels were all performed according to the instruc-
tions of the manufacturer of the STA-R analyser (Diagnostica Stago, Asnières, France). 
Fibrinogen (g/L) was determined according to methods of Clauss. [12] Levels of pro-
thrombin, factors VIII, IX, XI, (one-stage clotting assays) and antithrombin (amidolytic 
assay) were measured as activity assays with mechanical clot detection methods. Mean 
coagulation factor levels were compared between the different methods of sample 
handling using a Student’s paired t-test. Mean differences with 95% confidence intervals 
(CI) were calculated.
In addition, Bland-Altman plots were used to visualise the differences in coagula-
tion factor levels between different storage conditions (on the y-axis) versus the mean 
coagulation factor level of the two storage conditions (x-axis). [13] The 95% limits of 
agreement of the three methods of storage were assessed to evaluate if the magnitude 
of the measurements affected the mean and the standard deviation of the difference.
results
The mean levels of the measured coagulation factor levels in tube A (immediately 
processed), tube B (processed after 2.5 hours storage at room temperature), and tube C 
(processed after 2.5 hours storage on ice) are shown in table 1. The table also shows the 
mean differences in coagulation factor levels among the three methods of sample han-
dling. None of the coagulation factor levels (fibrinogen, prothrombin, factor VIII, factor 
IX, factor XI, and antithrombin) were affected by varying the time between venipuncture 
and centrifugation as shown by the mean differences between tubes A and B. Varying 
storage temperature, i.e., room temperature (tube B) versus cold storage on ice (tube C), 
only affected the measured levels of fibrinogen and coagulation factor VIII. For fibrino-
gen the mean difference was -0.014 g/L. By contrast, measured factor VIII levels were 
16% lower after 2.5 hours of storage on ice compared with immediate centrifugation. 
Bland-Altman plots showed that the differences of the mean levels and their standard 
deviations were not influenced by the mean levels of fibrinogen, prothrombin, factor 
VIII, factor IX, factor XI and antithrombin, i.e., the difference between measured levels 
after different storage conditions was similar for individuals with high or low coagula-
tion factor levels (Data not shown).
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disCussion
Guidelines for blood sample storage time and temperature prior to centrifugation for 
coagulation factors are only available for von Willebrand factor and factor VIII, and are 
based on only a few studies. [8,9] We demonstrate here that time to centrifugation of 
blood samples up to 2.5 hours does not affect the levels of prothrombin, antithrombin 
and factors VIII, IX and XI. These findings are in accordance with the results of Favaloro 
et al. who reported no effect of time to centrifugation up to 3.5 hours, or differences 
in storage temperature (room temperature versus cold storage) for measurement of 
coagulation factors II, V, VII, IX, X, XI, XII. [8]
We also observed that sample temperature prior to centrifugation influenced fibrino-
gen and FVIII levels. The lower level of factor VIII in our study after exposure to a cold 
environment supports the idea that cold-activation of factor VIII may occur, so levels are 
less accurate after storage in a cold environment. [8,9] Differences for fibrinogen were 
too small to be of relevance.
In conclusion, we demonstrated that storage of blood samples on ice resulted in lower 
levels of coagulation factor VIII, and did not alter the levels of prothrombin, factor IX, 
factor XI and antithrombin. Moreover, somewhat higher fibrinogen levels were found 
after storage of the tubes on ice. Potentially, the effect of storage temperature may differ 
among different subgroups of the study population, e.g., a different coagulation factor 
activation in men and women, however the small study size did not allow us to perform 
subgroup analyses. Storage of the blood samples at room temperature for up to 2.5 
table 1. Mean levels of coagulation factors in different storage conditions
n=10 mean difference (95% confidence interval)
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Tube A: direct processing. Tube B: room temperature (approximately 21°C), processing after 2.5 h. Tube C: 
cold environment (approximately 4°C), processing after 2.5 h. Mean differences with the 95% confidence 
intervals were calculated with Student’s paired t-test.
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hours prior to processing did not affect the measurement of the coagulation factor lev-
els. This indicates that research studies where samples are drawn in participant homes 
or other non-laboratory settings, can obtain reliable coagulation factor level results 
when storing the samples at room temperature rather than on ice.
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In this discussion section we will summarise the main results of this thesis and possible 
implications of the findings, discuss methodological considerations and focus on future 
perspectives in the AT-AGE study.
In chapter 2 we provided an overview of the available publications (up to 2010) on the 
effect of conventional risk factors as well as age-specific risk factors for venous throm-
bosis in the older population. Many conventional risk factors for venous thrombosis 
established in the young and middle-aged population appeared to increase the risk of 
thrombosis in the older population as well. Previous reports showed that immobilisation 
by hospital admission, malignant diseases, heart failure and genetic mutations ((factor 
V Leiden (FVL, rs6025) and prothrombin 20210A mutation (PT20210, rs1799963)) are risk 
factors for venous thrombosis in older individuals. As the prevalence of acquired risk fac-
tors is higher in the older than in the younger population we found higher population 
attributable risks (PAR). However, it must be noted that most risk estimates in the older 
population were based on studies with a small sample size or on subgroup analyses. 
Furthermore, only a limited number of studies concerning age-specific risk factors such 
as functional decline and endothelial dysfunction have been published. So, there was 
limited knowledge regarding risk factors for venous thrombosis in the older popula-
tion. In order to study the effect of conventional and age-specific risk factors for venous 
thrombosis in the older population, the “Age and Thrombosis, Acquired and Genetic risk 
factors in the Elderly” (AT-AGE) study was performed. The AT-AGE study is a population 
based case-control study among individuals aged 70 years and older for whom home 
visits were performed. [1]
In chapter 3 we demonstrated that short-term immobility at home, e.g., due to minor 
injuries or infections, is a risk factor for venous thrombosis in the older population (2- to 
5-fold increased risk). Furthermore, we illustrated that also hospitalisation is a major risk 
factor in older individuals, similar as in the young and middle aged individuals. Recent 
hospital discharge was identified as a risk factor, as the risk of venous thrombosis within 
two weeks after hospitalisation was still increased up to 15-fold. Surgery and plaster 
cast increased the risk of thrombosis up to 7-fold and fractures increased the risk up to 
13-fold. We demonstrated that the relative contribution of in-hospital immobility and 
out-hospital immobility to the incidence of venous thrombosis is high. Preventive drugs, 
i.e., thrombosis prophylaxis with low-molecular weight heparin is frequently given to 
older individuals during hospitalisation. [2] Our results indicate that extended thrombo-
prophylaxis after discharge may be beneficial. This notion is supported by results from 
the EXCLAIM trial, which included individuals aged 75 years and older. [3] Prolonged du-
ration of treatment after discharge reduced thrombosis rates (absolute difference in the 
30 days thrombosis rate −4.2% [95% CI: −6.5-2.0]) but this came at the cost of increased 
bleeding rates (30 days event rate: 0.5-0.8%). Prolonged use of thromboprophylaxis may 
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be justified in older individuals who are at particularly high risk of venous thrombosis 
in whom the benefit of treatment will outweigh the risk of major haemorrhage. Future 
studies need to carefully examine for which patients and risk circumstances the balance 
of treatment would be beneficial.
In chapter 4 we showed that genetic risk factors also play a role in the risk of venous 
thrombosis in older individuals. Factor V Leiden (FVL, rs6025) and the prothrombin 
20210A mutation (PT20210, rs1799963) increased the risk of thrombosis 1.5 to 2-fold 
in the older population. Also a positive family history of venous thrombosis remained 
associated with an increased risk of venous thrombosis in 70 years and older individuals 
(OR 2.3, 95% CI 1.6-3.3) These results indicate that genetics play a role in the etiology of 
venous thrombosis in older people, and that the effect is not limited to the young.
In chapter 5 and 6 we showed that age-specific risk factors are relevant in the devel-
opment of thrombosis. Venous stasis, a risk factor for thrombosis described already by 
Virchow, can be present due to diminished venous function or a damaged venous wall, 
causing venous insufficiency. Clinical features of venous insufficiency increased the risk 
of thrombosis in individuals aged 70 years and older. Varicose veins were associated 
with a 1.6-fold increased risk of venous thrombosis, and both a leg ulcer and leg oedema 
increased the risk of thrombosis 3-fold. The combination of these three clinical features 
showed a 10-fold increased risk of thrombosis compared to none of the clinical features. 
These increased risks could not be explained by the presence of other major risk factors 
of thrombosis in the older population, such as recent hospitalisation and surgery. We 
showed in chapter 6 that an impaired functional status, more specifically the disability 
to perform activities of daily living, having an impaired mobility, having a sedentary life, 
or an impaired hand grip strength were associated with a 2- to 4-fold increased risk of 
thrombosis. Therefore, in the older population not only short term immobility due to 
hospitalisation and minor injuries, (chapter 2), but also a long term state of decreased 
mobility and functioning was shown to increase the risk of thrombosis.
methodoloGiCAl ConsiderAtions of the At-AGe study
In the AT-AGE study we achieved high participation rates in cases (69%) and control 
subjects (73%) for questionnaires combined with blood sampling at first visit (chap-
ter 3). In chapter 7 we demonstrate that performing home visits rather than inviting 
participants to a study centre is an effective approach to increase the participation rate 
of older patients in research studies. Home visits enabled us to conduct an extensive, 
structured interview and to obtain a blood sample. We were able to visit less mobile 
individuals which diminished the threshold for participating. However, immediate pro-
cessing of blood samples in the laboratory is not feasible when conducting home visits. 
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For this reason we determined optimal sample handling, i.e., blood sample storage time 
and temperature prior to centrifugation with regard to the measurement of coagulation 
factor levels at a later stage in the study (chapter 8). We concluded that determina-
tion of coagulation factor levels was reliable when blood samples were stored at room 
temperature for up to 2.5 hours.
In the AT-AGE study, individuals with an active malignancy were excluded. Exclusion 
of individuals with an active malignancy preserved internal validity, as we anticipated 
that control subjects with an active malignancy would be less likely to participate in 
a research study than cases who suffered from a malignant disease. Moreover, selec-
tion bias was a potential problem due to recruitment of cases in the Netherlands via 
anticoagulation clinics, which only treat patients with vitamin K antagonists. Since 2007, 
patients with venous thrombosis and a malignancy are increasingly using low-molecular 
weight heparin injections instead of vitamin K antagonists, which would have led to an 
undersampling of venous thrombosis patients with a malignancy. [2]
In each case-control study there is a chance of recall bias. The risk of recall bias is not 
similar for all risk factors in our study. A risk factor such as a history of oedema of the 
legs in DVT patients probably has a higher chance to be affected by recall bias than 
the presence of more severe diseases such as leg ulcera. We performed standardised 
interviews by trained personnel, instead of a questionnaire by mail, which enabled us to 
clarify the questions for each participant, and determine more precisely the presence of 
risk factors in cases and control subjects. With this we reduced the chance of recall bias 
occurring in the AT-AGE study.
Relative risks found in etiological research within the older population tend to be 
lower than relative risks found in a younger population, due to the higher baseline risk 
of diseases in the older population. To be able to compare the relative influence of a risk 
factor on the incidence of venous thrombosis between the younger and the older popu-
lation, we assessed the population attributable risk (PAR). This enabled us to identify risk 
factors for venous thrombosis that exhibit major consequences on a population level, 
albeit with a mild relative risk of thrombosis.
future PersPeCtiVes
Multimorbidity is frequently present in the older population, and therefore it would be 
useful to evaluate within the AT-AGE study population, the role of the medical history 
of diseases in the older individuals. For example, it could be hypothesised that arterial 
disease, lung disorders such as chronic obstructive pulmonary diseases (COPD), chronic 
kidney disease, or hypothyroidism influence the risk of thrombosis in older individuals. 
Recent analyses in the AT-AGE study show that individuals with COPD have a 1.8-fold 
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increased risk of thrombosis compared with individuals without COPD (CI95 1.1-2.9: 1.1-
2.9). (Karasu et al, manuscript in preparation) Furthermore, it is currently not known what 
the effect is of multimorbidity on the risk of thrombosis, i.e., is interaction between these 
risk factors present? More insight into medication use as a potential risk factor or as a 
preventive factor for thrombosis in the older population is needed, as polypharmacy is 
frequently present in the older population. For instance, the potential protective effect 
of statin use on thrombosis risk in the older population could be determined. With age, 
plasma levels of many hemostatic factors are increasing, such as of fibrinogen, FVIII, FVII, 
D-dimer and homocysteine. [4,5] With the AT-AGE study we will gain insight in the role 
of these elevated levels of coagulation factors and the risk of venous thrombosis in the 
older population. In the younger population a venous thrombotic event most frequently 
presents itself as a DVT, whereas in the older population PE is more frequently diagnosed. 
[6] PE and DVT have long been thought to have the same etiology. However, recently 
it was shown that risk factors for DVT and PE sometimes differ. [7] The Factor V Leiden 
paradox is the well-established notion that this genetic variant affects predominantly 
the risk of DVT and not of PE. Lung disorders such as pneumonia and COPD, however, 
are risk factors for PE, but have little or no effect on DVT in the middle-aged population. 
A similar difference was recently demonstrated in the 70 years and older population of 
the AT-AGE study (COPD: ORPE 2.5, 95%CI: 1.4-4.3; ORDVT 1.0, 95%CI: 0.5-2.1). (Karasu et al, 
manuscript in preparation) In older individuals it would be interesting to define more risk 
factors specifically for PE, as PE is more common and is associated with higher mortality 
rates as compared to DVT. [6]
Follow up of the participating patients in the AT-AGE study has taken place one 
year after the thrombotic event when we revisited the patients and obtained data 
from questionnaires and a blood sample. With these data, we will able to evaluate the 
prevalence and severity of the post-thrombotic syndrome in patients aged 70 years 
and older. Furthermore, the effect of the occurrence of venous thrombosis on the qual-
ity of life within older individuals can be evaluated. It will be interesting to perform 
additional follow-up of the AT-AGE study patients and focus on the recurrence risk of 
thrombosis, the development of co-morbidities, and the mortality risk after thrombosis 
at higher age.
In a separate project, patients with deep venous thrombosis of the leg (n= 76) and 
control subjects (n=97) of the AT-AGE study are included to study the process of ageing 
of the venous valves (valve thickness and function) and the risk of venous thrombosis 
(BATAVIA study). (Karasu et al, manuscript in preparation) These subjects underwent an 
ultrasound examination of the venous valves in the popliteal veins.
In general, future research should focus on the use of preventive measures of venous 
thrombosis within the highest risk groups in the older people. In this thesis we indicate 
that extended thromboprophylaxis might be beneficial in older individuals who are at 
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high risk of thrombosis. However, the risk of major hemorrhage needs to be taken into 
account. The role of direct oral anticoagulant (DOAC) drugs within specific risk groups 
can be explored. These DOACs are used as thromboprophylaxis in orthopedic surgery. 
However, beneficial effects on prevention of venous thrombosis in the older popula-
tion are currently unknown. The ADOPT trial showed that apixaban was associated with 
more major bleeding events than enoxaparin in middle aged and older people (>40 
years). [8] Moreover, an antidote is not yet available. Other medications that have been 
suggested to prevent thrombosis are aspirin and statins. Aspirin may be a good option 
for prevention in the older population. [9] The preventive effect is lower than that of 
low molecular weight heparin and oral anticoagulants; however, the bleeding risk is 
low. If further research confirms the protective effect of statins, this would be, if well-
tolerated by the patients, an elegant alternative in the prevention of thrombosis in the 
older population. [10,11] The effect of preventive measures for thrombosis other than 
medication, such as compression stockings, frequent ambulation, or the use of electrical 
calf muscle stimulation are important targets of future research in the older population. 
For now, physicians could advise patients with in and out-of-hospital immobility to walk 
a few times per day, or to perform exercises of the calf muscles even while being bedrid-
den, to prevent stasis. [12]
Currently,’ the primary care rule’, a clinical decision rule, is used to rule out DVT in 
primary care together with the point of care D-dimer assay. [13] Recently, it was found 
that in older patients the primary care rule showed a higher failure rate than in younger 
patients. [14] This might indicate that other predictors of thrombosis are present and 
needed in the older individuals. It would be interesting to investigate the addition of 
age-specific risk factors, such as functional impairment, short-term immobility at home, 
or minor injuries in order to improve the clinical decision rule in the older population.
ConClusions
Venous thrombosis will lead to increasing medical and economic burdens in the near 
future, given the worldwide growth of the older population. Determining risk factors 
of thrombosis specific in older individuals provides insight in opportunities to prevent 
thrombosis in this age group. Research studies in older individuals are challenging; 
however, we showed that performing home visits rather than inviting participants to 
a study centre can be an effective approach to increase the participation rate of older 
patients. In this thesis we showed that conventional risk factors such as immobilisation 
due to hospital admission and also immobility at home, due to for instance infection 
and minor injury, increase the risk of venous thrombosis also in 70 years and older 
individuals. We report the presence of age-specific risk factors: venous insufficiency and 
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functional impairment. The relative contribution of these risk factors to the incidence 
of venous thrombosis in this population is high. We identified new high risk groups in 
older people, e.g., recent hospital discharge in which preventive measures could be 
of special interest. In the upcoming years the AT-AGE study will provide information 
on additional risk factors for venous thrombosis in the older population. With further 
identification of risk factors and high-risk groups within the older population we can 
put effort into research focusing on adaptation of diagnostic rules and the safe use of 
preventive measures.
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Stolselvorming is een natuurlijk en onmisbaar mechanisme dat ervoor zorgt dat schade 
aan een bloedvat hersteld wordt, zodat er geen grote hoeveelheid bloedverlies optreedt. 
Schade aan het bloedvat leidt tot vrijkomen van weefselfactor in het bloed. Dit induceert 
de omzetting van factor X in actief factor X (factor Xa), waarna activatie van protrombine 
naar trombine optreedt. Trombine zorgt voor de omzetting van fibrinogeen tot fibrine. 
Bloedplaatjes aggregeren bij de plek van de bloedvatschade en vormen samen met 
fibrine een bloedstolsel. Dit bloedstolsel is het resultaat van een delicate balans tus-
sen pro- en antistollende processen. Als het bloedvat voldoende is gerepareerd wordt 
de stollende activiteit verminderd door plasmine, waardoor het fibrinestolsel oplost. 
Echter, indien het stollingsproces overactief is, of indien er geen vermindering van de 
stollingsactiviteit plaatsvindt, ontstaat overmatige bloedstolling. Deze overmatige stol-
selvorming kan de aders blokkeren ten koste van de normale bloeddoorsstroming. [1] 
Het blokkeren van aders door een stolsel wordt veneuze trombose genoemd. De twee 
meest voorkomende vormen van veneuze trombose zijn diep veneuze trombose van 
het been (DVT) en embolisatie van een of meerdere stolsels naar de longarteriën, ofwel 
een longembolie (LE).
Veneuze trombose komt jaarlijks bij 1 per 1000 personen per jaar. [2] Bij jongeren 
en mensen van middelbare leeftijd zijn in de afgelopen decennia veel risicofactoren 
van veneuze trombose vastgesteld, zoals immobilisatie, orale anticonceptie, operatie, 
fracturen en gips. Ook genetische factoren, zoals de factor V Leiden mutatie, verhogen 
het risico op veneuze trombose. [3]
Leeftijd is een belangrijke risicofactor voor veneuze trombose: ten opzichte van 40-50 
jarigen hebben 80 jarigen een 10x verhoogd risico op het ontwikkelen van trombose. [4] 
In de gehele westerse wereld, neemt het aantal ouderen toe. In de aankomende 50 jaar 
zal de 70+ populatie verviervoudigen. [5] In Nederland is 15% van de bevolking 65 jaar 
en ouder en dit zal toenemen tot 25% in de aankomende 30 jaar. [6] Deze verandering in 
leeftijdsverdeling zal leiden tot een toename van zowel de prevalentie als de incidentie 
van ziekten zoals veneuze trombose, leidend tot een hogere medische en economische 
last in de toekomst. Door de stijging van de incidentie van trombose met de leeftijd is 
het van belang om de etiologie van veneuze trombose bij ouderen op te helderen, zodat 
adequate preventieve maatregelen ingezet kunnen worden.
In de 19e eeuw zijn drie mechanismen beschreven die tot stolselvorming kunnen 
leiden en bekend zijn geworden als de trias van Virchow: (1) stase van de bloedstroom, 
(2) schade aan het bloedvat (b.v. door hypoxie) en (3) veranderingen in de bloedsa-
menstelling. [7] Risicofactoren van veneuze trombose zijn veelal terug te voeren op 1 
of een combinatie van deze drie elementen. Vooralsnog is er onvoldoende kennis over 
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de risicofactoren van veneuze trombose bij de meest aangedane groep, de ouderen. Dit 
wordt uiteengezet in hoofdstuk 2. 
In hoodstuk 2 presenteren we een overzicht van de tot dus ver (tot 2010) verschenen 
artikelen die risicofactoren van veneuze trombose bij ouderen en jongeren vergelijkt. 
Veel conventionele risicofacteren voor veneuze trombose, oftewel risicofactoren die 
geïdentificeerd zijn in jongeren en patiënten van middelbare leeftijd, lijken ook van 
toepassing in de oudere populatie. De gepubliceerde onderzoeken geven aan dat im-
mobilisatie door ziekenhuisopname, maligniteiten, hartfalen en genetische mutaties 
(factor V Leiden (FVL, rs6025) and prothrombin 20210A mutatie (PT20210, rs1799963), 
risicofactoren zijn voor trombose bij de ouderen. Omdat de prevalentie van de “verkre-
gen” risicofactoren bij ouderen hoger is dan bij jongeren werd er een hoger populatie 
attributief risico (PAR) gevonden bij de ouderen. Echter, een belangrijk nadeel van deze 
onderzoeken is dat ze vaak uitgevoerd zijn in kleine groepen. Bovendien, waren slechts 
een aantal onderzoeken gericht op leeftijdsspecifieke risicofactoren, zoals functionele 
achteruitgang en endotheel disfunctie. We concluderen dat er beperkte kennis was van 
de risicofactoren voor veneuze trombose bij de ouderen. Met deze reden is het Age 
and Thrombosis, Acquired and Genetic risk factors in the Elderly studie (AT-AGE-studie) 
opgezet, een patiënt-controle onderzoek in twee centra (in Leiden, Nederland en Bur-
lington, Vermont, Verenigde Staten). In Leiden werden van juni 2008 tot augustus 2011 
en in Vermont werden van december 2008 tot juli 2011, alle opeenvolgende patiënten 
ouder dan 70 jaar met een DVT in het been of een LE geïdentificeerd. In Nederland 
werden patiënten die werden aangemeld bij de trombosedienst (Leiden of Haarlem) 
met een DVT of LE benaderd. In Vermont werden patiënten benaderd in het vasculair la-
boratorium en de radiologie afdeling van de University of Vermont Health Centre in Bur-
lington. De controlepopulatie bestaat uit deelnemers die willekeurig zijn geselecteerd 
uit huisartsenpraktijken in Leiden en Vermont. De AT-AGE studie is specifiek ontworpen 
om inclusie van de oudere populatie te faciliteren. Om het deelnemerspercentage te 
optimaliseren zijn bijvoorbeeld huisbezoeken afgelegd. Er is een uitgebreid interview 
afgenomen, waarin werd gevraagd naar conventionele en potientiële leeftijdsspecifieke 
risicofactoren voor veneuze trombose. Tevens werd gedurende deze huisbezoeken een 
bloedafname gedaan en zijn er fysieke testen uitgevoerd zoals de handkrachtmeting. 
Veel analysen in dit proefschrift zijn gebaseerd op dit onderzoek, waarin 401 opeenvol-
gende patiënten ≥70 jaar oud met een eerste trombose en 431 controle deelnemers ≥70 
jaar oud zonder een trombose in de voorgeschiedenis, geincludeerd zijn. 
In hoofdstuk 3 beschrijven we de studiepopulatie en het onderzoeksdesign van de 
AT-AGE studie. Bovendien laten we zien dat kortdurende immobiliteit in de thuissituatie, 
bijvoorbeeld door een blessure of een infectie een risicofactor is voor veneuze trombose 
in de ouderen (2 tot 5 x verhoogd risico). Het blijkt dat ziekenhuisopname, net als bij 
jongeren en bij mensen van middelbare leeftijd, een belangrijke risicofactor is voor 
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trombose. Tevens hebben we gevonden dat een recent ontslag uit het ziekenhuis een 
risicofactor is. Het risico op trombose was twee weken na thuiskomst uit het ziekenhuis 
tot 15 keer verhoogd ten opzichte van de groep zonder een recente ziekenhuisopname. 
Een operatie en gips verhoogde de kans op veneuze trombose 7 keer, en botbreuken 13 
keer in vergelijking met het niet hebben van deze risicofactoren. Omdat de prevalentie 
van deze immobiliteit in een oudere populatie hoog is, vonden we een hoog populatie 
attributief risico (PAR) voor zowel ziekenhuisgerelateerde immobiliteit (27%) en voor im-
mobiliteit in de thuissituatie (15%). Preventieve maatregelen, zoals trombose profylaxe 
met laagmoleculair-gewicht heparine, wordt frequent gegeven aan ouderen tijdens 
een ziekenhuisopname. [8] Onze resultaten geven aan dat het langer geven van zulke 
tromboseprofylaxe na ontslag uit het ziekenhuis mogelijk gunstig zou kunnen zijn. Dit 
wordt bevestigd door de resultaten van de EXCLAIM trial uitgevoerd in individuen van 
75 jaar en ouder. [9] In deze studie leidde verlenging van de duur van tromboprofylaxe 
na ziekenhuisopname tot een vermindering van het optreden van trombose (30 dagen 
absolute verschil in trombose: −4.2% [95% CI: −6.5-2.0%]). Echter, het zorgde wel voor 
een verhoging van het aantal bloedingen (in 30 dagen: 0.5-0.8% bloedingsrisico). Wij 
stellen dat langduriger gebruik van tromboseprofylaxe mogelijk gegrond is bij ouderen 
die in het bijzonder een verhoogd risico hebben op veneuze trombose, waarbij de 
behandeling opweegt tegen het risico op bloedingen. 
In hoofdstuk 4 laten we zien dat genetische risicofactoren een rol spelen bij veneuze 
trombose in ouderen. Factor V Leiden (FVL, rs6025) en de prothrombine 20210A mutatie 
(PT20210, rs1799963) verhogen het risico op trombose 1.5 tot 2-keer in de oudere po-
pulatie. Een positieve familie anamnese is ook geassocieerd met een verhoogd risico op 
veneuze trombose in ouderen boven de 70 jaar (OR 2.3, 95%BI 1.6-3.3). Deze resultaten 
geven aan dat genetica een rol blijft spelen in de etiologie voor veneuze trombose, ook 
in ouderen. 
In hoofdstuk 5 en 6 worden leeftijd-specifieke risicofactoren geïdentificeerd die rele-
vant zijn bij de ontwikkeling van trombose. Virchow beschreef al dat veneuze stase een 
risicofactor voor trombose is. [7] Stase van bloed kan ontstaan door een verminderde 
functie of beschadiging van de aderen, leidend tot veneuze insufficientie. Wij laten zien 
dat klinische kenmerken van veneuze insufficientie het risico op trombose in ouderen 
boven de 70 jaar verhogen. Spataderen zijn geassocieerd met een 1.6 keer verhoogd 
risico op veneuze trombose. Een voorgeschiedenis van een ulcus cruris verhoogde het 
risico 3 keer, evenals het hebben van oedemen in de benen. De combinatie van deze 
drie klinische factoren liet een 10 keer verhoogd risico op trombose zien vergeleken met 
het niet hebben van deze factoren. Deze risicoschattingen werden niet verklaard door 
de aanwezigheid van andere belangrijke risicofactoren van de oudere populatie zoals 
recente ziekenhuisopname en operatie.
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We laten in hoofdstuk 6 zien dat een verminderde functionele status leidt tot een 
verhoogd risico op trombose. We hebben gekeken naar: verminderde validiteit bij de 
algemene dagelijkse levensverrichttingen (ADL), verminderde mobiliteit, een zittende 
leefstijl en een verminderde handknijpkracht. Al deze vier manifestaties verhoogden 
afzonderlijk het risico op veneuze trombose 2 tot 4 keer. Hoe meer manifestaties er aan-
wezig waren hoe hoger het risico op trombose. Concluderend, in de oudere populatie 
leidt niet alleen kortdurende immobilteit door bijvoorbeeld ziekenhuisopname of een 
blessure tot een hoger trombose risico (hoofdstuk 2), maar ook een langdurige staat 
van verminderde mobiliteit en functie verhoogd dit risico.
methodoloGisChe oVerWeGinGen bij de At-AGe studie
De deelnemerspercentages in de AT-AGE studie zijn hoog, 69% van de patiënten en 73% 
van de controles deden mee met het eerste huisbezoek bestaande uit een interview met 
vragenlijst en een bloedafname (hoofdstuk 3). In hoofdstuk 7 laten we zien dat het 
doen van huisbezoeken in vergelijking met het uitnodigen van deelnemers naar een 
onderzoekscentrum, een effectieve manier is om het deelnemerspercentage in ouderen 
te verhogen. Een huisbezoek heeft het mogelijk gemaakt om een uitgebreid en gestruc-
tureerd interview uit te voeren en tegelijkertijd een bloedafname te doen. Het verlaagt 
de drempel tot deelname aan onderzoek voor minder mobiele patiënten. Echter, door 
het uitvoeren van huisbezoeken was het niet mogelijk de bloedafname direct in het 
laboratorium te bewerken. Daarom hebben we bekeken wat de meest optimale werk-
wijze is voor de bloedafname ten aanzien van de duur en de temperatuur van deze 
bloedafnameopslag, met als doel de stollingsfactoren te bepalen in een latere fase van 
het onderzoek (hoofdstuk 8). We concluderen dat de bepaling van coagulatiefactoren 
betrouwbaar is indien het afgenomen bloed opgeslagen wordt op kamertemperatuur 
tot 2 ½ uur. Dit is geïmplementeerd in de AT-AGE studie.
In de AT-AGE studie zijn individuen met een actieve maligniteit geëxludeerd van deel-
name. Met deze exclusie hebben we de interne validiteit behouden, aangezien we heb-
ben geanticipeerd op het feit dat controles met een actieve maligniteit mogelijk minder 
zouden deelnemen aan het onderzoek dan patiënten die een trombose doormaken 
en een maligniteit hebben. Bovendien, omdat we in Nederland de patiënten via de 
trombosediensten hebben gerecruteerd is er kans op selectiebias, aangezien sinds 2007 
patiënten met een veneuze trombose en een maligniteit vaak behandeld worden met 
een laagmoleculair-gewicht heparine injecties in plaats van belandeling met vitamine K 
antagonisten in een trombosedienst. [8] Dit zou kunnen leiden tot lagere steekproef van 
patiënten met een maligniteit bij recruteren bij de trombosedienst.
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In elke case-control studie is er kans op recall bias. Het risico op recall bias is niet gelijk 
voor alle bestudeerde risico factoren in dit proefschrift. Bij een risicofactor zoals een 
voorgeschiedenis van oedemen in de benen bij een patiënt met een DVT is het risico op 
bias hoger dan bij ernstigere ziekten zoals een ulcus cruris. Gedurende de huisbezoeken 
hebben we gestandaardiseerde interviews gehouden door getraind personeel, in plaats 
van een vragenlijst per post. Dit maakte het mogelijk om alle vragen duidelijk uit te 
leggen aan alle deelnemers, en de aanwezigheid van risicofactoren bij patiënten en 
controles goed te documenteren. Hiermee is gepoogd de kans op recall bias zo laag 
mogelijk te maken in de AT-AGE studie.
Relatieve risico’s die in etiologische onderzoeken worden gevonden in de oudere 
populatie hebben de neiging lager te zijn dan in de jongere populatie, door een hoger 
basisrisico op ziekten in de oudere populatie. Om de relatieve invloed van een risico-
factor op de incidentie van een veneuze trombose te vergelijken in de jongeren en 
ouderen hebben we de PAR berekend. Dit maakt het mogelijk om risicofactoren voor 
veneuze trombose te identificeren die grote consequenties op populatie niveau heb-
ben, ofschoon er een mild relatief risico op trombose is.
ConClusies en imPliCAties
Met een wereldwijde groei van de oudere populatie zal veneuze trombose, in toene-
mende mate, een hogere medische en economische last in de toekomst worden. Het 
determineren van risicofactoren voor veneuze trombose specifiek in ouderen geeft 
mogelijkheden voor preventieve maatregelen in deze leeftijdsgroep. Het uitvoeren van 
onderzoek in ouderen is uitdagend, echter, met de AT-AGE studie laten we zien dat het 
uitvoeren van huisbezoeken een effectieve mogelijkheid is om het deelnemerspercen-
tage te verhogen. In dit proefschrift laten we zien dat conventionele risicofactoren voor 
veneuze trombose, zoals immobilisatie door ziekenhuisopname en ook immobiliteit in 
de thuissituatie, het risico op veneuze trombose bij individuen van 70 jaar en ouder 
verhoogt. We hebben leeftijdsspecifieke risicofactoren voor veneuze trombose geïden-
tificeerd: veneuze insufficientie en vermindering in de functionele status leiden tot 
een hoger risico op veneuze trombose. De prevalentie van deze risicofactoren is hoog 
waardoor de relatieve bijdrage van deze risicofactoren op de incidentie van veneuze 
trombose in de ouderen hoog is. Door deze kennis zijn hoog-risicogroepen voor ve-
neuze trombose bij ouderen geindentificeerd. Preventieve maatregelen voor veneuze 
trombose bij ouderen die recentelijk ontslagen zijn uit het ziekenhuis verdient extra 
aandacht. Het langer geven van tromboseprofylaxe, nu vaak in de vorm van laagmole-
culair-gewicht heparine, is mogelijk gunstig voor de ouderen die een hoog risico heb-
ben op trombose, hoewel het tegen het risico op bloedingen moet worden afgewogen. 
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Mogelijk is hier een rol weggelegd voor de directe orale anticoagulantia (de DOACs). 
Een nadeel hierbij kan zijn dat een antidotum nog niet aanwezig is. Het gebruik van 
andere medicatie die mogelijk het risico op trombose verlagen zijn aspirine en statines. 
Aspirine zou een goede optie zijn in de oudere populatie. [10] Het preventieve effect 
is lager dan bij gebruik van laagmoleculair-gewicht heparine en orale anticoagulantia, 
maar het bloedingsrisico is laag. Als verder onderzoek laat zien dat statines het risico 
op trombose daadwerkelijk kan verlagen, zou dit een elegant alternatief zijn. [11,12] 
Andere preventieve, niet medicamenteuze maatregelen zijn belangrijk om te onder-
zoeken in de oudere populatie, bijvoorbeeld het gebruik van steunkousen, elektrische 
kuitspierstimulatie en het stimuleren van systematisch bewegen van de benen. Op dit 
moment kunnen artsen de patiënten met immobiliteit in het ziekenhuis, of in de thuis-
situatie adviseren om een aantal keren per dag te lopen, en om kuitspier oefeningen 
te verrichten. Ook als de patiënt hele dagen in bed ligt zou het goed zijn om dit uit te 
voeren, zodat stase van de bloedstroom voorkomen wordt. [13]
Ons onderzoek naar risicofactoren voor veneuze trombose bij ouderen is van belang 
om nieuwe risicofactoren te detecteren binnen de meest aangedane groep. Deze ken-
nis kan bijdragen aan het determineren van voorspellende factoren van trombose en 
voor het verder optimaliseren van klinische beslisregels voor DVT en LE. Er bestaat een 
“eerste lijnsbeslisregel”, dit is een klinische beslisregel die gebruikt wordt om DVT uit te 
sluiten in de huisartspraktijk samen met een point of care D-dimeer test. [14] Recentelijk 
is gebleken dat deze beslisregel in ouderen niet optimaal werkt. [15] Het determineren 
van andere voorspellers voor trombose in ouderen is dus nodig. Het zou interessant zijn 
om de rol van de leeftijds-specifieke risicofactoren in deze beslisregels te onderzoeken.
In de aankomende jaren zal de AT-AGE studie nog aanvullende informatie gaan bren-
gen over risicofactoren in ouderen. Met de verdere identificatie en kwantificatie van het 
effect van de conventionele en de leeftijdsspecifieke risicofactoren in ouderen en het 
determineren van hoog-risicogroepen, kan verder onderzoek zich richten op aanpas-
singen van diagnostische beslisregels voor veneuze trombose en het veilig gebruik van 
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